Male contraception

By using an immunotherapy strategy targeting the zona pellucida protein ZP3, testicular spermatogenesis is inhibited, providing a reversible male contraceptive method that overcomes the irreversibility and side effects of existing male contraceptive methods, achieving safe and effective contraception.

CN118900696APending Publication Date: 2024-11-05SCIENCEMED SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280084384.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-10-19
Filing Date
2022-10-18
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing male contraceptive methods have issues with irreversibility, side effects, and safety concerns, and there is a lack of effective, safe, and reversible male contraceptive drugs.

Method used

A reversible male contraceptive strategy is provided by using zona pellucida proteins, particularly ZP3 protein, to suppress spermatogenesis in the testes through an immune response. This strategy includes immunogenic peptides, T cells, and specific antibodies to perform immunotherapy on sperm cells expressing ZP protein.

Benefits of technology

It achieves a temporary and reversible state of male infertility, with fertility restored after treatment termination, avoiding long-term side effects and providing a safe and effective contraceptive effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900696A_ABST
    Figure CN118900696A_ABST
Patent Text Reader

Abstract

The present invention relates generally to methods of contraception in male subjects, which may be human or non-human mammals. The present inventors have unexpectedly found that zona pellucida (ZP) proteins, in particular zona pellucida protein 3 (ZP3), are expressed in spermatogonium, spermatoblasts and rounded and slender sperm cells of human and mouse testis, but are not present in mature sperm, supporting cells, interstitial cells, spermatogonial stem cells and progenitor cells. Based on these findings, zona pellucida proteins, in particular ZP3, constitute suitable targets for immunocontraception strategies, in particular strategies intended to induce transient and reversible male sterility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to a method of contraception for male subjects, which may be human or non-human mammals. More specifically, the present invention relates to an antigenic source providing at least one immunogenic portion of a protein expressed by spermatogonia, spermatocytes and sperm but not by testicular Sertoli cells, Leydig cells, spermatogonial stem cells and progenitor cells, preferably a zona pellucida (ZP) protein, especially a ZP3 protein. Such an antigenic source can be used in vaccines and pharmaceutical compositions for reversible male contraceptive treatments. Background of the Invention

[0003] Women have a variety of contraceptive methods to choose from, but male contraceptive options are still limited. Condoms are the most popular option, but there are some disadvantages, such as decreased sensation and the need for caution when using them. The second option is vasectomy, but this method is invasive and largely irreversible. Male contraceptive methods based on hormones (androgens alone or in combination with progestins) have been widely tested, but have failed to completely suppress spermatogenesis in all men. In addition, these methods involve giving relatively high doses of testosterone and progestin preparations, which often cause side effects such as acne, mood changes, weight gain, night sweats, and changes in libido. There have been concerns about the safety of long-term use of androgens. Currently, there are several projects to develop hormone-based male contraceptives (e.g., male contraceptives using nestorone-testosterone gel or progestational androgen-dimethylandrosol 17β-undecone) underway, but their sufficient efficacy and safety have not yet been proven.

[0004] Clearly, the development of a male contraceptive is a major medical challenge, and an effective, reversible male contraceptive remains unmet. The ideal male contraceptive would be effective, safe, fully reversible, and accessible to a broad range of potential users. Other considerations include reducing the time required for the regimen to take effect and to reverse, minimizing and identifying "nonresponders," and determining long-term safety.

[0005] The object of the present invention is to provide novel immunotherapeutic strategies for male contraception. Summary of the invention

[0006] The present inventors have surprisingly found that zona pellucida (ZP) proteins, in particular zona pellucida protein 3 (ZP3), are expressed in spermatogonia, spermatocytes and round and elongated spermatids of human and mouse testes, but are absent in mature spermatozoa, Sertoli cells, Leydig cells, spermatogonial stem cells and progenitor cells. Based on these findings, zona pellucida proteins, in particular ZP3, constitute suitable targets for immunocontraceptive strategies, in particular strategies aimed at inducing temporary and reversible male infertility.

[0007] ZP3 is normally present in the so-called 'zona pellucida' in females, which forms the extracellular matrix surrounding the oocyte. This zona pellucida induces the acrosome reaction of sperm, determines the species specificity of fertilization and prevents polyspermy in mammals.

[0008] Female immunocontraception based on ZP protein is well established, especially in large wild animals (see, e.g., Gupta and Minhas, Frontiers In Bioscience, 2017, Scholar, 9, 357-374, http: / / www.bioscience.org / 2017 / v9s / af / 492 / 2.htm; Mask et al., 2015, Theriogenology; 84(2): 261-267). A number of studies have been conducted in which the decline in fertility is associated with antibody titers (Shresta et al., 2015, Vaccine 33, 133-140; Harris et al., 1999, Protein Expr Purif; 16(2): 298-307; Martinez and Harris, 2000, J Reprod Fertil.; 120(1): 19-32).

[0009] WO 89 / 03399 relates to immunocontraception in women using monoclonal zona pellucida antibodies or zona pellucida antigens (which elicit an antibody response). According to WO 89 / 03399, anti-ZP antibodies inhibit fertilization by interfering with sperm binding to or penetration of the zona pellucida without adversely affecting ovarian function. The method is said to induce temporary infertility by affecting the sperm zona pellucida response.

[0010] The present method does not rely on inhibiting sperm binding to or penetration of the zona pellucida, but rather relies on inhibiting spermatogenesis in the testis, i.e., by eliciting an immune response against spermatogonia, spermatocytes and / or spermatids found to express ZP protein.

[0011] The concept of eliciting humoral and / or cellular immune responses against ZP proteins and cancer cells ectopically expressing ZP has been proposed and demonstrated to be useful for treating certain cancer types. Rahman et al. (A novel therapeutic strategy for ovarian cancer based on zona pellucida protein (ZP) 3 immunity. FASEB J. 2012 Jan;26(1):324-33) demonstrated that malignant ovarian tumors in transgenic mice can be treated by eliciting humoral and cellular vaccination against ZP3 protein and cells expressing ZP3, respectively. These findings and similar findings have also been described in the following: International Patent Publication Nos. WO2007 / 058536, which relates to immunotherapy methods for treating ovarian cancer; WO2019 / 086507, which relates to immunotherapy methods for treating lung cancer; WO2012 / 026820, which relates to immunotherapy methods for treating prostate cancer; and WO2016080830, which relates to immunotherapy methods for treating pancreatic cancer.

[0012] The expression of ZP protein in spermatogonia, spermatocytes and spermatids, or any other cell type normally present in the testis, has never been previously found in humans or animals. Therefore, the present invention provides for the first time a method of contraception in male subjects based on a humoral and / or cellular immune response against the ZP protein. Since the testicular Sertoli cells, Leydig cells, spermatogonial stem cells and progenitor cells do not express the ZP protein (and therefore are not targeted by the immune response), spermatogenesis can be restarted and normal fertility can be restored after the ZP3 treatment is stopped and the immune response abates. Rahman et al. have demonstrated that the immune response against the ZP protein may be temporary (FASEB J. 2012 Jan;26(1):324-33, as described above). These findings mean that the infertility state induced by the methods of the present invention may be temporary / reversible.

[0013] Thus, a first aspect of the present invention relates to a method of treating a male subject, in particular a method of contraception for a male subject, the method comprising administering a pharmaceutical composition comprising:

[0014] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0015] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0016] c) an antibody or fragment thereof that specifically binds to hZP;

[0017] Preferably, the hZP protein is human zona pellucida protein 3 (hZP3).

[0018] Another aspect of the present invention relates to a pharmaceutical composition comprising:

[0019] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0020] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0021] c) an antibody or fragment thereof that specifically binds to hZP;

[0022] Preferably, the hZP protein is human zona pellucida protein 3 (hZP3) for use in a method for treating a male subject, particularly a contraceptive method for a male subject.

[0023] Yet another aspect of the present invention relates to the following:

[0024] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0025] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0026] c) an antibody or fragment thereof that specifically binds to hZP;

[0027] Preferably, the hZP protein is human zona pellucida protein 3 (hZP3), and use thereof in the preparation of a pharmaceutical composition for a method for treating a male subject (especially a contraceptive method for a male subject).

[0028] Other aspects of the present invention relate to pharmaceutical compositions comprising:

[0029] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0030] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0031] c) an antibody or fragment thereof that specifically binds to hZP;

[0032] Preferably, the hZP protein is human zona pellucida protein 3 (hZP3); and a kit comprising a package containing one or more such pharmaceutical unit dosage forms, and instructions containing printed instructions for administering one or more of the unit dosage forms in a male subject / as a contraceptive method in a male subject.

[0033] It should be understood that, unless otherwise explicitly stated, these aspects of the present invention all relate to the same composition, the same treatment method, the same object, etc. Based on the following detailed description and the additional experimental part, the specific details and preferred embodiments of the above methods and the compositions and pharmaceutical kits used therein will be clear to those skilled in the art. DETAILED DESCRIPTION

[0034] For the method of the present invention, the subject to be treated is preferably male, and can be a human or non-human mammal. Preferably, the subject to be treated is male. The method can be implemented on any male subject of childbearing age. In a preferred embodiment of the present invention, the subject is a male aged 16 years or more, preferably 18 years or more, 20 years or more, 25 years or more, 30 years or more, or 35 years or more.

[0035] In certain embodiments of the invention, the subject to be treated does not suffer from lung cancer, prostate cancer or pancreatic cancer and / or any pathology directly related thereto. In certain embodiments of the invention, the subject to be treated does not suffer from lung cancer, prostate cancer or pancreatic cancer and / or any pathology directly related thereto, wherein the cancer cells express one or more or all ZP proteins. In further embodiments of the invention, the subject does not suffer from any disease or pathology involving ZP proteins and / or cells expressing ZP. In certain embodiments of the invention, the subject is a healthy subject.

[0036] The terms "treat", "treatment" or "treatment" used herein in direct connection with 'a subject' (e.g.: "a method of treating a subject") generally refer to the act of administering a pharmaceutical composition to said subject, whether for therapeutic or non-therapeutic purposes. This should not be confused with the terms "treat", "treat" or "treatment" used in connection with a specific disease or condition (e.g.: "a method of treating a disease ..."), in which case these terms do imply therapeutic or preventive purposes.

[0037] As is apparent from the foregoing explanations herein, the method for treating a male subject according to the present invention will generally affect spermatogenesis, thereby leading to an infertile state, decreased fertility, inability to impregnate a female sexual partner, and the like. Therefore, in a particularly preferred embodiment of the present invention, a method as defined herein is provided, wherein the method is a male contraceptive method. In other embodiments of the present invention, a method as defined herein is provided, wherein the method is a method for reducing male fertility, a method for inducing male infertility, a method for inhibiting spermatogenesis, a method for inducing oligospermia, a method for inducing azoospermia, a method for significantly reducing sperm count, a method for inducing a severe oligospermia state, a method for reducing MOT, a method for reducing TMS, and / or a method for reducing semen volume. In one embodiment of the present invention, the method results in a sperm count of less than 5.10 6 sperm / ml semen, for example, less than 2.5·10 6 sperm / ml semen, less than 1.10 6 sperm / ml semen, less than 5.10 5 sperm / ml semen or less than 1.10 5 sperm / ml of semen, or preferably simply no sperm.

[0038] In a preferred embodiment of the invention, the treatment effect as defined above is reversible or temporary. In a particularly preferred embodiment of the invention, male fertility parameters, such as sperm count, sperm motility, MOT, TMS and semen volume, return to more than 50% of the baseline level after the treatment is terminated, such as more than 60%, more than 70%, more than 80% or more than 90%, wherein the baseline level refers to the level before the treatment begins. In a particularly preferred embodiment of the invention, male fertility parameters, such as sperm count, sperm motility, MOT, TMS and semen volume, return to more than 50% of the average level of normal fertile males after the treatment is terminated, such as more than 60%, more than 70%, more than 80% or more than 90%. Typically, the male fertility parameters return to the indicated levels within 5 years after the treatment is terminated, such as within 4 years, within 3 years, within 2.5 years, within 2 years, within 1.5 years, within 1 year, within 10 months, within 8 months, within 6 months, within 5 months, within 4 months or within 3 months.

[0039] Based on this teaching, it will be appreciated by those skilled in the art that the method of the present invention may need to repeat the treatment of male subjects, i.e., by giving a booster dose of the pharmaceutical composition defined herein. Therefore, in certain embodiments of the present invention, a method as defined herein is provided, wherein the pharmaceutical composition of a contraceptive effective amount is given once every 3 years, once every 2 years, once a year, once every 10 months, once every 8 months, once every 6 months, once every 5 months, once every 4 months, once every 3 months, once every 2 months, or once a month to treat male subjects. Based on this teaching, it will be appreciated by those skilled in the art that as long as male subjects wish to maintain an infertile state (or, if male subjects are non-human mammals, as long as it is desired that the non-human mammals maintain an infertile state), male subjects may continue to be treated according to the scheme. In certain embodiments of the present invention, the method includes repeated administration of the pharmaceutical composition of the present invention, preferably according to the scheme defined herein, for at least 6 months, more preferably at least 9 months, at least 12 months, at least 2 years, at least 3 years, at least 4 years, or at least 5 years.

[0040] As used herein, the term "contraceptive effective" means "sufficient to achieve a contraceptive effect", which will be understood by those skilled in the art based on the present teachings. In general, a "contraceptive effective amount" refers to a dose or amount sufficient to achieve any one or any combination of the effects defined above and / or a dose or amount sufficient to induce a primary (auto) immune response against (native) ZP glycoprotein and cells expressing ZP protein. Such an effective dose will depend on a variety of factors, including the patient's condition and overall health status. Therefore, based on the present teachings, trained medical personnel can determine and adjust the dosage regimen to provide the best therapeutic or preventive effect.

[0041] The term "pharmaceutical composition" as used herein refers to any compound, material, composition and / or dosage form that is suitable for administration to mammals, especially humans, in a certain enteral (extragastric) form within the scope of reasonable medical judgment without causing excessive toxicity, irritation, allergic reaction and other complications, and with a reasonable benefit / risk ratio.

[0042] As defined above, the method of the present invention comprises administering a pharmaceutical composition comprising:

[0043] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0044] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0045] c) an antibody or fragment thereof that specifically binds to hZP;

[0046] Preferably, the hZP protein is human zona pellucida protein 3 (hZP3), and the composition is generally administered in a contraceptively effective dose or amount.

[0047] As used herein, the term "zona pellucida protein" generally refers to any protein found in the zona pellucida of humans or mammals. The zona pellucida is a specialized extracellular matrix surrounding the developing oocyte (egg, ovum) within each follicle in the ovary. This matrix is ​​thought to be formed by secretions from the oocyte and granulosa cells of the follicle, and in the human oocyte consists of four types of zona pellucida glycoproteins, ZP1, ZP2, ZP3, and ZP4, which have different roles in fertilization. Over the years, the nomenclature of the ZP glycoprotein components has been somewhat inconsistent, and a variety of criteria including apparent molecular weight, protein sequence length, and sequence identity comparisons have been used, leading to confusion in the nomenclature. Harris et al. [(1994) DNA seq. 96: 829-834] proposed a unified nomenclature in which ZP genes are named in order from the longest to the shortest length of the protein sequence they encode. According to these criteria, since the order of the mouse ZP genes is ZP2, ZP1, ZP3, a new system was introduced in which ZP2 became ZPA, ZP1 became ZPB, and ZP3 became ZPC. Hughes et al. [(1999) BBA-Gene Structure and Expression 1447:303-306] reported that the true human ortholog of the known mouse ZP1 gene is not ZPB, but that different human ZP1 genes exist. It is now generally believed that there are four different (human) ZP glycoprotein families, ZP1, ZP2, ZP3 and ZPB [see Lefievre et al. (2004) Hum. Reprod. 19:1580-1586]. According to this nomenclature, the ZPB glycoprotein is now also called ZP4. This nomenclature is applied, for example, to the Uniprot / SWISSprot, ensEMBL, BLAST (NCBI), SOURCE, SMART, STRING, PSORT2, CDART, UniGene and SOSUI databases, all of which are available in the Bioinformatic Harvester ( http: / / harvester.embl.de ) is implemented.

[0048] Accordingly, the terms ZP1, ZP2, ZP3 and ZP4 are used herein to represent the four ZP glycoprotein families, wherein ZP2, ZP3 and ZP4 correspond to ZPA, ZPC and ZPB, respectively, which is consistent with the nomenclature proposed by Harris et al. More specifically, the terms hZP1, hZP2, hZP3 and hZP4 used herein refer to proteins having the polypeptide backbones listed in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4, respectively, and their allelic variants.

[0049] According to the present invention, the ZP protein is most preferably a ZP3 protein.

[0050] The corresponding terms ZP and hZP also encompass allelic variants of ZP sequences that may occur in nature. Allelic variants particularly include variants produced by single nucleotide polymorphisms (SNPs). SNPs may fall into the coding sequence of a gene, the non-coding region of a gene, or the intergenic region between genes. SNPs in the coding sequence do not necessarily change the amino acid sequence of the protein produced. Two forms of SNPs that result in the same polypeptide sequence are called synonymous mutations (sometimes referred to as silent mutations)-if different polypeptide sequences are produced, they are non-synonymous. To consider a variant as a SNP, it must appear in at least 1% of the population. In the context of the present invention, `allelic variants' can also include polypeptide sequence variants produced by (non-synonymous) mutations, i.e., polypeptide variants produced by point mutations, insertions, deletions, etc. that appear in less than 1% of the population.

[0051] Therefore, according to the present invention, the terms hZP1, hZP2, hZP3 and hZP4 include ZP proteins that differ from SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4, respectively, by minor sequence modifications. Such modifications include, but are not limited to, changes in one or several amino acids, including deletions (e.g., truncated versions of the peptides), insertions and / or substitutions.

[0052] 'Allelic variant' is understood herein as having an amino acid sequence identity of at least 90%, preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, even more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% to any one of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4.

[0053] Each ZP protein comprises a signal peptide that directs it to the secretory pathway, a zona domain, and a transmembrane domain located near the carboxyl terminus, followed by a short cytoplasmic tail. In embodiments of the invention comprising administering antibodies or fragments thereof that specifically bind to hZP, the antibodies or fragments thereof are preferably directed against the ZP extracellular domain. In embodiments of the invention involving active immunization, the immunogenic polypeptide source capable of eliciting a cellular immune response against hZP can, in principle, be used any portion of hZP that comprises class I MHC restricted T cell epitopes and / or class II MHC restricted T cell epitopes.

[0054] The amino acid sequence of the hZP3 nascent protein contains an N-terminal signal peptide sequence protein (amino acid positions 1-22 in SEQ ID NO: 3), a conserved "ZP extracellular domain" (amino acid positions 23-350 in SEQ ID NO: 3), and a propeptide (amino acid positions 351-424 in SEQ ID NO: 3), which is composed of a consensus furin cleavage site (CFCS; amino acid positions 351-352 in SEQ ID NO: 3), an external hydrophobic patch (EHP) that blocks polymerization, and a C-terminal transmembrane domain (amino acid positions 353-424 in SEQ ID NO: 3). The hZP3 signal peptide is cleaved during translation, and cleavage at the CFCS separates the mature hZP3 extracellular domain protein (consisting of amino acid positions 23-350 in SEQ ID NO: 3) from the EHP, enabling it to be incorporated into nascent ZP filaments. Therefore, the amino acid backbone of the mature hZP3 extracellular domain has an amino acid sequence consisting of amino acid positions 23-350 in SEQ ID NO: 3 of hZP3. This extracellular domain fragment is referred to herein as hZP3(23-350) (SEQ ID NO: 5).

[0055] In a preferred embodiment, the present invention relates to a method of treatment by active immunization. The method of active immunization preferably comprises administering an immunogenic polypeptide source capable of inducing a cellular immune response against human zona pellucida protein (hZP), preferably hZP3 or hZP3 (23-350); T cells comprising a T cell receptor that binds to an MHC-peptide complex, wherein the peptide is a peptide from hZP, preferably from hZP3 or hZP3 (23-350); an antibody or fragment thereof that specifically binds to hZP, preferably binds to hZP3 or hZP3 (23-350); and a genetic construct comprising a nucleic acid sequence encoding the polypeptide or antibody, wherein the genetic construct is configured to be delivered and expressed in the human body.

[0056] The immunogenic polypeptide source can be a protein material source, a nucleic acid or a combination thereof. The protein material source can be, for example, a composition comprising one or more peptides, polypeptides or proteins acting as immunogens. Alternatively, the immunogenic polypeptide source can be a nucleic acid molecule encoding one or more immunogenic peptides, polypeptides or proteins, which expresses immunogenic peptides, polypeptides or proteins when administered to the object to be treated. The nucleic acid molecule can be DNA, cDNA RNA, mRNA, a variant thereof, a fragment thereof or a combination thereof, such as, for example, described in WO2014 / 165291 and WO2013 / 087083. The immunogenic polypeptide source can also be a cell expressing an immunogenic polypeptide or presenting an immunogenic polypeptide epitope, preferably a living cell. Preferably, the cell is a microorganism, more preferably a bacterium, such as, for example, an attenuated live monocytogenes Listeria, such as described in WO2015 / 164121. Alternatively, the cellular source of the immunogenic polypeptides of the present invention is autologous or allogeneic dendritic cells that present at least one epitope of the immunogenic polypeptide in an HLA molecule on their surface.

[0057] In a preferred embodiment, the immunogenic polypeptide comprises a continuous amino acid sequence selected from the amino acid sequence of hZP protein, which preferably comprises at least one of a class I MHC restricted T cell epitope and a class II MHC restricted T cell epitope. More preferably, the immunogenic polypeptide comprises a continuous amino acid sequence selected from the amino acid sequence of hZP3 protein (i.e., SEQ ID NO: 3), which preferably comprises at least one of a class I MHC restricted T cell epitope and at least one class II MHC restricted T cell epitope, for example, selected from Tables I, II and III, respectively (as attached to the specification). More preferably, the continuous amino acid sequence comprises at least one of a class I MHC restricted T cell epitope and a class II MHC restricted T cell epitope with a low percentile rank (see Moutaftsi et al., Nat Biotechnol. 2006 July; 24(7): 817-9 and; Kotturi et al., J Virol. 2007 May; 81(10): 4928-40). A class I MHC restricted T cell epitope with a low percentile rank is preferably an epitope with a percentile rank no higher than 1.00, 0.80, 0.40, 0.30, 0.20, 0.15, 0.10 or 0.05 (see, e.g., Tables I and III). A class II MHC restricted T cell epitope with a low percentile rank is preferably an epitope with a percentile rank no higher than 2.50, 2.40, 2.05, 2.00, 1.80, 1.60, 1.40, 1.20, 1.10, 1.00, 0.90, 0.70, 0.60, 0.50, 0.40, 0.20. 0.15, 0.10, 0.05 or 0.02. Preferably, the contiguous amino acid sequence is selected from the group of amino acid sequences of proteolytic hZP3 fragments, the group consisting of an N-terminal signal peptide sequence (positions 1-22 in SEQ ID NO: 3), a mature extracellular domain sequence (positions 23-350 in SEQ ID NO: 3, i.e., SEQ ID NO: 5) and a propeptide sequence (amino acid positions 351-424 in SEQ ID NO: 3). Fig.13 Examples of such contiguous amino acid sequences are given.

[0058] The continuous amino acid sequence of the hZP (3) protein contained in the immunogenic polypeptide preferably comprises an immunologically active (sequence) fragment of the hZP (3) protein. The term "immunologically active fragment thereof" is generally understood in the art to refer to a fragment of the hZP (3) protein antigen comprising at least one epitope, which means that the immunogenic polypeptide comprises at least 4, 5, 6, 7 or 8 consecutive amino acids from the hZP (3) protein antigen sequence. According to the present invention, the fragment comprises at least one class I MHC or class II MHC binding peptide presented to the immune system by such MHC molecules. The 'immunologically active fragment' according to the present invention comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 consecutive amino acids from the sequence of the ZP protein antigen or its homologue or analogue. Although most MHC binding peptides are 9 amino acids in length, longer peptides can be accommodated by the bulge in their central portion (Guo et al., 1992, Nature; 360(6402): 364-366; Speir et al., 2001, Immunity; 14(1): 81-92), resulting in binding peptides of 8 to 15 amino acids in length (Schumacher et al., 1991, Nature; 350(6320): 703-706). Tables 2 and 5 give examples of class I MHC binding peptides in the hZP3 sequence. The size of peptides that bind to class II proteins is not limited (Nelson et al., 1999, Rev Immunogenet; 1(1): 47-59; Yassai et al., 2002, J Immunol; 168(3): 1281-1285), ranging from 11 to 30 amino acids in length (Rammensee 1995, Immunogenetics; 41(4): 178-228), and may even be entire proteins. However, the binding motif is about 9 amino acids long. Class II MHC can accommodate longer peptides than class I MHC because the ends of the class II MHC binding groove are open, so either end of the epitope (which binds to the groove) may be flanked by additional amino acid stretches. Table II gives examples of class II MHC binding peptides in the hZP3 sequence (i.e., SEQ ID NOs. 39-65). Even more preferably, the fragment comprises cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes. However, most preferably, the fragment is a peptide that requires antigen presenting cell processing, i.e., the length of the fragment is at least about 18 amino acids, which are not necessarily continuous sequences from the hZP (3) protein antigen.

[0059] Therefore, the length of the continuous amino acid sequence of the hZP (3) protein contained in the immunogenic polypeptide or the length of the immunogenic polypeptide itself is preferably at least 18, 19, 20, 21, 22, 25, 27, 30, 33 or 35 amino acids, and preferably not more than 100, 80, 60, 50, 45, 40, 35, 33 or 30 amino acids. The length of the continuous amino acid sequence of the hZP (3) protein contained in the immunogenic polypeptide or the length of the immunogenic polypeptide itself is preferably 19-50 or 19-45 amino acids, more preferably 25-40 amino acids, even more preferably 25-35 amino acids, and most preferably 25-30 amino acids. From the perspective of manufacturability, an immunogenic polypeptide of about 25 amino acids in length is optimal, while still being long enough to contain multiple epitopes and be strongly presented by antigen presenting cells (force presentation). Fig.13 Suitable examples of such immunogenic polypeptides are shown, which include contiguous amino acid sequences from the hZP3 protein and each contain one or more MHC class I and / or MHC class II binding peptides.

[0060] As used herein, the term "homolog thereof" refers to a polypeptide that differs from a naturally occurring polypeptide by minor modifications but retains the basic polypeptide and side chain structure of the naturally occurring form. Such changes include, but are not limited to: changes in one or several amino acid side chains; changes in one or several amino acids, including deletions (e.g., truncated versions of peptides), insertions and / or substitutions; changes in the stereochemistry of one or several atoms; and / or minor derivatizations, including, but not limited to, methylation, glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and / or addition of glycosylphosphatidylinositol. As used herein, a homolog or analog has an enhanced or substantially similar function compared to a naturally occurring polypeptide. Typically, when optimally aligned, such as by using the programs GAP or BESTFIT using default parameters, a naturally occurring polypeptide and its homologs share at least a certain percentage of sequence identity. GAP uses the Needleman and Wunsch global alignment algorithm to align the full length of two sequences, maximizing the number of matches and minimizing the number of gaps. Typically, using the GAP default parameters, a gap creation penalty = 8 and a gap extension penalty = 2. For proteins, the default scoring matrix is ​​Blosum62 (Henikoff and Henikoff, 1992, PNAS 89, 915-919). Sequence alignments and percentage sequence identity scores can be determined using a computer program, such as the GCG Wisconsin software package, version 10.3, available from Accelrys Inc. (9685 Scranton Road, San Diego, California 92121-3752, USA). Alternatively, percentage similarity or identity can be determined by searching databases (e.g., FASTA, BLAST, etc.).

[0061] Homologues herein are understood to include immunogenic polypeptides having at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 95%, even more preferably at least 98% and most preferably at least 99% amino acid sequence identity with the above-mentioned naturally occurring ZP polypeptides and still being able to elicit at least the immune response obtainable thereby. Homologues or analogs herein may include substitutions, insertions, deletions, additional N-terminal or C-terminal amino acids and / or additional chemical moieties (e.g. carbohydrates) to increase stability, solubility and immunogenicity.

[0062] According to the present invention, the immunogenic polypeptide administered to humans according to the present method may be or include a protein or glycoprotein, a digest of a protein or glycoprotein and / or a fragment thereof, which may be in a purified form or may be contained in a crude composition, preferably of biological origin, such as a lysate, sonication product or fixative of a prokaryotic or eukaryotic cell line. However, more preferably, the immunogenic polypeptide is or includes a chemically synthesized (poly)peptide or an in vitro enzymatically produced (poly)peptide, which may be in a purified form or may be contained in a crude composition.

[0063] As used herein, the term "epitope" refers to a portion of an antigen, usually defined by a short peptide, which, when present in a physiologically relevant environment in vivo, is capable of eliciting a cellular or humoral immune response. "T cell epitope" refers to a short peptide or portion thereof that binds to an MHC molecule and, when present in certain MHC molecules, can be recognized by certain T cells. T cell epitopes are capable of inducing a cell-mediated immune response by being presented directly or indirectly in heterodimeric membrane MHC molecules. Preferably, in the immunogenic polypeptide, at least one class II MHC restricted epitope and at least one class I MHC restricted epitope are present within a contiguous amino acid sequence of the amino acid sequence from the hZP (3) protein, wherein preferably, the class II MHC restricted epitope and at least one class I MHC restricted epitope are selected from Table II, Table I and Table III, respectively. For clarity, the peptides of the present invention preferably comprise at least one class I MHC presented epitope, and preferably also comprise at least one class II MHC presented epitope. Each of these epitopes is presentable and will bind to a corresponding specific MHC molecule present on a cell after being treated as described herein. Therefore, each MHC restricted epitope may also be referred to as an MHC binding and / or presentable epitope. Preferably, a specific proteasomal cleavage site at the C-terminus that generates such an epitope is present just after the amino acid sequence of the epitope so that it is released from the immunogenic polypeptide and presented on the class I MHC molecule. For class II MHC presented epitopes, the length requirement is less stringent, and therefore the need for precise enzymatic generation of class II binding peptides is less absolute. In short, MHC molecules preferentially bind to specific amino acid residues known as "anchor" residues (K. Falk et al., Nature 351: 290-96 (1991)). This feature allows class I and class II MHC binding motifs to be recognized in any known peptide sequence (see, e.g., Tables I, III and II).

[0064] In this context, the term "MHC restricted epitope" is synonymous with T cell epitope. The term "class I MHC restricted epitope" as used herein refers to a peptide sequence recognized by class I MHC-associated cytotoxic T lymphocytes (also known as CD8+ cells, TCD8 or CTL). The term "class II MHC restricted epitope" as used herein refers to a peptide sequence recognized by class II MHC-associated helper T cells (also known as CD4 +A "B cell epitope" is a peptide recognized by a T cell (such as a T cell, TCD4 or HTL). A "B cell epitope" is a part of an antigen that is capable of binding to the antigen binding site of an immunoglobulin and is therefore capable of stimulating a humoral response in the absence of presentation by an MHC molecule. As previously described, a polypeptide useful in the present invention or a nucleic acid encoding the polypeptide comprises at least one T cell epitope. However, the present invention does not exclude the use of polypeptides that also comprise B cell epitopes. The immunogenic polypeptides of the present invention may also include multiple T cell epitopes, as well as optional B cell epitopes. When multiple epitopes are present in a peptide, the epitopes may be oriented in series or in a nested or overlapping configuration, wherein at least one amino acid residue may be shared by two or more epitopes.

[0065] The immunogenic polypeptides of the present invention preferably comprise one or more MHC class I restricted epitopes. As is generally known to those skilled in the art, antigens comprising a single MHC restricted epitope can only be used to treat a (small) subset of patients expressing the product of an MHC allele capable of binding to that particular peptide. It has been calculated that in humans, a vaccine containing CTL epitopes restricted by HLA-A1, -A2, -A3, -A24 and -B7 will cover about 80% of individuals of most ethnic backgrounds. Therefore, if the method is used to treat humans, it is particularly preferred that the method comprises administering a composition comprising one or more different polypeptides comprising one, more preferably two, most preferably three MHC class I binding natural ZP (preferably hZP3) epitopes selected from the group consisting of HLA-A1, HLA-A2, HLA-A3, HLA-A24 and HLA-B7 restricted epitopes; or homologs thereof.

[0066] According to another embodiment, the immunogenic polypeptide of the present invention preferably includes one or more class II MHC restricted epitopes. The most common class II MHC allele products in humans include HLA-DR1, -DR3, -DR4 and -DR7. Therefore, the method preferably includes administering a composition comprising one or more different polypeptides, wherein the one or more different polypeptides include one, more preferably two, and most preferably three class II MHC binding natural ZP (preferably hZP3) epitopes selected from HLA-DR1, HLA-DR3, HLA-DR4 and HLA-DR7 restricted epitopes; or homologs thereof.

[0067] In another embodiment, the method of the present invention comprises administering a composition comprising one or more polypeptides comprising one or more MHC class I restricted epitopes and one or more MHC class II restricted epitopes, as described above and / or in Tables 2, 5 and 3, respectively; or homologs thereof. Even more preferably, the composition comprises an effective amount of one or more different polypeptides, which together comprise substantially all MHC class I and MHC class II binding epitopes contained in one of the native ZP (preferably hZP3) glycoproteins; or homologs of said one or more polypeptides.

[0068] In one embodiment, the method comprises administering a composition comprising one or more different immunogenic polypeptides. Preferably, the one or more different polypeptides collectively comprise at least 50%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% and most preferably at least 95% of the class I and class II MHC restricted epitopes contained in native ZP (preferably hZP3 or hZP3 (23-350)) or homologs of the one or more polypeptides.

[0069] In a preferred embodiment, the method comprises administering a Fig.13 , for example, an immunogenic peptide comprising or consisting of one or more amino acid sequences selected from SEQ ID NO. 66-75. Therefore, the composition may comprise one of the immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO. 66-75. However, preferably, the composition comprises a combination of at least two of the immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO. 66-75.

[0070] In another preferred embodiment, the method comprises administering a composition comprising one or more immunogenic peptides comprising or consisting of an epitope selected from the epitopes shown in Table III (i.e., SEQ ID NO.76-85). Thus, the composition may comprise one of the immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO.76-85. However, preferably, the composition comprises a combination of at least two of the immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO.76-85. Particularly preferred compositions comprise one or more or all immunogenic peptides comprising or consisting of an amino acid sequence of SEQ ID NO.79, 80, 81, 83 and 84.

[0071] In a preferred embodiment, the method comprises administering an immunogenic polypeptide source comprising at least 50%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% and most preferably at least 95% of the complete amino acid backbone of a native ZP (preferably hZP3 or hZP3 (23-350)) glycoprotein; or a homolog of said polypeptide.

[0072] In a particularly preferred embodiment, the method comprises administering a composition comprising a source of an immunogenic polypeptide comprising 90%, 95%, 97%, 98%, 99% or 100% of the complete amino acid backbone of the extracellular domain of native ZP (preferably hZP3 or hZP3 (23-350)) or a homologue of said polypeptide. The immunogenic polypeptides as defined hereinabove may be glycosylated. Without wishing to be bound by theory, it is assumed that by glycosylation of these polypeptides, their immunogenicity is increased at least to the extent that they elicit a humoral (B cell response). Thus, the immunogenic polypeptides as defined hereinabove are preferably glycosylated and have a carbohydrate content varying from 10-80 wt.%, 15-70 wt.% or 20-60 wt.%, based on the total weight of the glycoprotein or glycosylated polypeptide. Preferably, the glycosylated immunogenic polypeptide comprises a glycosylation pattern similar to the corresponding native human zona ZP glycoprotein.

[0073] In another particularly preferred embodiment, the method comprises administering an immunogenic polypeptide source, which is a composition comprising an effective amount of a plurality of different overlapping polypeptide fragments of a native ZP (preferably hZP3 or hZP3 (23-350)) glycoprotein, wherein the length of the different overlapping polypeptide fragments is between 18 and 60 amino acids, and together they comprise at least 50%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% and most preferably at least 95% of the complete amino acid backbone of the native ZP or the extracellular domain of the native ZP (preferably hZP3 or hZP3 (23-350) or a homologue of the polypeptide). More preferably, the length of the different overlapping polypeptide fragments is 25-40 amino acids, even more preferably 25-35 amino acids and most preferably 25-30 amino acids. Typically, the amino acid sequence overlap between different consecutive 18-60 amino acid polypeptide fragments is at least 7 amino acids, preferably at least 8 amino acids, more preferably at least 9 amino acids, and most preferably at least 10 amino acids.

[0074] The MHC binding motifs of the most common class I and class II MHC alleles have been described. These motifs list the amino acid residues that serve as the MHC binding anchors for specific class I and class II MHC alleles. Complex computer algorithms that take into account the amino acid sequence of the MHC binding anchors and peptides are used to predict and quantify the binding affinity of peptide / MHC interactions. Therefore, from the input of the known zona pellucida protein amino acid sequence, these algorithms list all potential T cell epitopes, each of which has its corresponding predicted binding score (see, e.g., Table I, III and II). Bioinformatics tools commonly used for these purposes include, for example, HLA-BIND (Parker et al., 1994, J. Immunol. 152: 163), SYFPEITHI (Rammensee et al., 1995, Immunogenetics 41, 178-228; Rammensee et al., Landes Bioscience 1997, International distributor Springer Verlag GmbH & Co. KG, Heidelberg, Germany; http: / / www.syfpeithi.de / ), NetMHC (Buus et al., 2003, Tissue Antigens., 62: 378-84; Nielsen et al., 2003, Protein Sci., 12: 1007-17; Nielsen et al., 2004, Bioinformatics, 20(9): 1388-97; http: / / www.cbs.dtu.dk / services / NetMHC / ), TEPITOPE 2000 (Stumiolo et al., 1999, Nature Biotechnology 17, 555-562; http: / / www.vaccinome.com / pages / 597444 / ) and the (continuously updated) IEDB analysis resource - T cell epitope prediction tool: http: / / tools.iedb.org / main / tcell / .

[0075] Alternatively, the skilled artisan will be able to determine HTL and CTL binding epitopes experimentally using standard assays (Current Protocols in Immunology, Wiley-Interscience 2004). In a preferred embodiment, the method comprises administering a composition comprising an effective amount of a plurality of different polypeptide fragments of a native ZP (preferably hZP3 or hZP3 (23-350)) glycoprotein, said polypeptide fragments being between 18 and 100 amino acids in length, wherein each polypeptide fragment comprises one or more of said predicted potential MHC class I or MHC class II restricted epitopes. Preferably, said predicted potential MHC class I or MHC class II restricted epitopes do not overlap in amino acid sequence in different polypeptide fragments. Preferably, a plurality of different polypeptide fragments collectively comprise at least 50%, 70%, 80%, 90% or 95% of the potential MHC class I or MHC class II epitopes predicted by one or more of the above-mentioned bioinformatics tools.

[0076] In some cases, it is observed that the same peptide may bind to several I or II class MHC allele products (see, e.g., Tables I, III, and II). In one embodiment, it is particularly preferred to use such a `promiscuous' MHC binding peptide in the present method.

[0077] The immunization method of the present invention preferably includes administering an immunogenic active polypeptide fragment source, the polypeptide fragment being selected from zona pellucida protein fragments and / or their homologues as defined above, the polypeptide fragment comprising CTL and / or HTL epitopes restricted by a variety of HLA molecules, and the fragment length being between 18 and 45 amino acids. It has been observed that peptides with a length between 18 and 45 amino acids have excellent immunogenic properties, as described in WO02 / 070006. The peptide can advantageously be synthesized chemically, and can optionally (partially) overlap and / or can also be connected to other molecules, peptides or proteins. It is also advantageous to add a chemical moiety or an additional (modified or D-) amino acid to the amino or carboxyl end of the peptide to increase the stability of the peptide and / or reduce its biodegradability. In order to improve the immunogenicity / immunostimulatory properties, the part can be attached, for example, by lipidation, extension and / or coupling (see below). The peptide can be extended, for example, by adding charged or polar amino acids, to enhance its solubility and / or increase its stability in vivo.

[0078] For immunization purposes, the above-mentioned immunogenic polypeptides of the present invention may also be fused to proteins, such as, but not limited to, tetanus toxin / toxoid, diphtheria toxin / toxoid or other carrier molecules. The polypeptides of the present invention may also advantageously be fused to heat shock proteins, such as recombinant endogenous (murine) gp96 (GRP94) as a carrier of immunodominant peptides, as described in (references: Rapp UK and Kaufmann SH, Int Immunol. 2004 April; 16(4): 597-605; Zugel U, Infect Immun. 2001; 69(6): 4164-7), or to fusion proteins of Hsp70 (Triebel et al.; WO99 / 54464). The immunogenic polypeptides of the present invention may also be coupled to molecules having adjuvant activity (as listed below), in particular TLR ligands / agonists as listed below.

[0079] The individual amino acid residues of the immunogenic (poly)peptides of the present invention can be incorporated into the peptide via peptide bonds or peptide bond mimetics. The peptide bond mimetics of the present invention include peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide carbonyl, α-carbon, amide nitrogen, complete replacement, extension, deletion or backbone cross-linking of amide bonds. See generally Spatola, Chemistry and Biochemistry of Amino Acids, Vol. VII (Weinstein, 1983). Several peptide backbone modifications are known, including ψ[CH2S], ψ[CH2NH], ψ[CSNH2], ψ[NHCO], ψ[COCH2] and ψ[(E) or (Z)CH=CH]. The nomenclature used above follows the nomenclature suggested by Spatola above. In this context, .psi. indicates the absence of an amide bond. The structure of the alternative amide group is specified in brackets.

[0080] Amino acid mimetics can also be incorporated into polypeptides. As used herein, "amino acid mimetics" are moieties other than naturally occurring amino acids that serve as conformational and functional substitutes for amino acids in the polypeptides of the invention. Such moieties serve as substitutes for amino acid residues if they do not interfere with the ability of the peptide to elicit an immune response against a native ZP T cell epitope. Amino acid mimetics can include non-protein amino acids, such as β-, γ-, δ-amino acids, β-, γ-, δ-imido acids (e.g., piperidine-4-carboxylic acid), and many derivatives of L-α-amino acids. Many suitable amino acid mimetics are known to those skilled in the art, including cyclohexylalanine, 3-cyclohexylpropionic acid, L-adamantylalanine, adamantylacetic acid, and the like. Peptide mimetics suitable for use in the peptides of the invention are discussed in Morgan and Gainor (1989) Ann. Repts. Med. Chem. 24: 243-252.

[0081] The method preferably includes administering the immunogenic polypeptides and compositions comprising them by parenteral or oral routes (preferably parenteral routes). Preferred routes of administration include, but are not limited to, intramuscular, intranasal, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, intraocular, and oral, as well as topical, transdermal, inhalation, or suppositories or mucosal tissues, such as by lavage of the vagina, rectum, urethra, buccal, and sublingual tissues. Preferred routes of administration include intramuscular, intraperitoneal, intradermal, and subcutaneous injections. In another embodiment, administration is into an anatomical site that drains to a lymph node basin. In another embodiment, administration is into multiple lymph node basins.

[0082] Particularly preferred is to combine the intradermal and subcutaneous administration of the drug of the present invention. The DC in the epidermis is significantly different from the DC in the dermis and the subcutis. Intradermal (intradermal) immunity will lead to antigen processing and activation of epidermal DC (Langehans protein (Langerin) positive Langerhans cells), which are in close contact with keratinocytes through their dendritic network. This will also optimally activate the inflammatory pathway in the interaction between Langerhans cells and keratinocytes, and then the Langerhans cells loaded with antigens and activated will be transported to the skin draining lymph nodes. Subcutaneous administration will activate other DC subsets, which will also load antigens and independently go to the skin draining lymph nodes. It is conceivable that the use of drugs that can be administered intradermally and subcutaneously may cause different DC subsets to synergistically stimulate the T cells in these drainage nodes.

[0083] Pharmaceutical compositions comprising one or more immunogenic polypeptides as defined above will generally also comprise at least one excipient. Excipients are well known in the pharmaceutical field and can be found, for example, in textbooks such as Remington's pharmaceutical sciences, Mack Publishing Company, 1995.

[0084] According to a preferred embodiment, a typical dosage regimen includes a dose of 1-1000 μg / peptide per immunization, more preferably 10-500 μg / peptide per immunization, and even more preferably 5-150 μg / peptide per immunization, at least once. Preferably, the dose is repeated once, twice, three times or more at intervals of 2, 3 or 4 weeks. According to a preferred embodiment, 5-150 μg / peptide is administered per immunization, and each treatment is repeated once or more within 2-3 weeks.

[0085] In the present method, one or more immunogenic polypeptides are usually administered at least once at a dose of about 1, 2, 5, 10, 20, 50, 100, 200, 500 or 1000 μg / immunogenic polypeptide or nucleic acid molecule or more. Preferably, the dose is repeated once, twice, three times or more at intervals of 2, 3 or 4 weeks.

[0086] In another preferred embodiment, the immunogenic polypeptide source of the present invention to be administered includes a nucleic acid molecule encoding an immunogenic polypeptide as defined above herein. The composition comprising such a nucleic acid molecule encoding an immunogenic polypeptide may comprise one or more different nucleic acid molecules encoding any one of the immunogenic polypeptides, polypeptide fragments and / or peptides as defined above. In addition, the nucleic acid molecule may encode a larger portion of a natural ZP. For example, the nucleic acid molecule may encode a polypeptide comprising at least 50%, 70%, 80%, 90%, 95% or 100% of the complete amino acid backbone of a ZP (preferably hZP3, more preferably hZP3 (23-350)) or a homologue of said polypeptide. Preferably, the nucleic acid molecule encodes a continuous stretch of at least 50%, 70%, 80%, 90%, 95% or 99% of the complete amino acid backbone. The nucleic acid molecule may also encode more than one (T cell epitope-containing) immunologically active fragment from the contiguous amino acid sequence of hZP (3) as defined above, whereby in the encoded amino acid sequence, different immunologically active fragments may be separated by spacer or linker sequences, like beads on a string.

[0087] The nucleic acid molecule encoding the immunogenic polypeptide of the present invention can be a DNA molecule, preferably a genetic construct, wherein the nucleotide sequence (cDNA) encoding the immunogenic polypeptide is operably linked to an appropriate expression control sequence to ensure that the immunogenic polypeptide is functionally expressed in the target cells of the human subject, for example, including at least one strong promoter (e.g., a viral promoter). Genetic constructs used as DNA vaccines include, for example, plasmids or viral vectors, particularly those described in WO2014 / 165291, WO2016 / 123285, and WO2017 / 136758.

[0088] Alternatively, the nucleic acid molecule encoding the immunogenic polypeptide of the invention can be an RNA molecule, such as mRNA, ssRNA, dsRNA or a combination thereof. The RNA molecule can, for example, be formulated into a particle comprising the molecule.

[0089] In certain particularly preferred embodiments of the present invention, the RNA is a messenger RNA (mRNA), which is directed to an RNA transcript encoding an immunogenic polypeptide of the present invention. As determined in the art, mRNA typically comprises a 5'-untranslated region (5'-UTR), a peptide coding region, and a 3'-untranslated region (3'-UTR). In some embodiments, the RNA is produced by in vitro transcription or chemical synthesis. In one embodiment, the mRNA is produced by in vitro transcription using a DNA template, wherein DNA refers to a nucleic acid containing deoxyribonucleotides.

[0090] In one embodiment, the RNA is an in vitro transcribed RNA (IVT-RNA), which can be obtained by in vitro transcription of an appropriate DNA template. The promoter controlling the transcription can be any promoter of any RNA polymerase. The DNA template for in vitro transcription can be obtained by cloning nucleic acids (particularly cDNA) and introducing them into an appropriate vector for in vitro transcription. The cDNA can be obtained by reverse transcription of RNA. In one embodiment, the RNA may have modified nucleosides. In some embodiments, the RNA contains modified nucleosides to replace at least one (e.g., each) uridine.

[0091] Common delivery methods and carrier molecules for RNA vaccines include: naked (m)RNA; naked (m)RNA with in vivo electroporation; protamine-complexed (m)RNA; (m)RNA associated with a positively charged oil-in-water cationic nanoemulsion; (m)RNA dendrimer nanoparticles (e.g. mRNA associated with chemically modified dendrimers and complexed with polyethylene glycol (PEG)-lipids); (m)RNA protamine liposomes (e.g. mRNA complexed with protamine in PEG-lipid nanoparticles); (m)RNA associated with a cationic polymer (e.g. polyethyleneimine or 'PEI'); (m)RNA cationic polymer liposomes (e.g. mRNA associated with a cationic polymer (e.g. PEI) and a lipid component). (mRNA); (m)RNA polysaccharide particles (e.g., mRNA associated with a polysaccharide such as chitosan, a particle or a gel); (m)RNA cationic lipid nanoparticles (e.g., mRNA in a cationic lipid nanoparticle, such as 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) or dioleoyl-phosphatidylethanolamine (DOPE) lipids); (m)RNA cationic-lipid-cholesterol nanoparticles (e.g., mRNA complexed with a cationic lipid and cholesterol); and (m)RNA cationic-lipid-cholesterol PEG nanoparticles (e.g., mRNA complexed with a cationic lipid, cholesterol and PEG-lipid); as described by Pardi et al. (mRNA vaccines-a newera in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261-279).

[0092] Therefore, one aspect of the invention relates to a pharmaceutical composition comprising RNA encoding an immunogenic polypeptide as defined above, in any of these forms or carrier types, and the use of these pharmaceutical compositions in any of the methods as defined above.

[0093] In a particularly preferred embodiment of the invention, the RNA is in the form of an RNA nanoparticle comprising an RNA encoding an immunogenic polypeptide as defined above,

[0094] In preferred embodiments of the invention, the average diameter of the RNA nanoparticles ranges from about 50 nm to about 1000 nm, about 75 nm to about 800 nm, about 100 to about 700 nm, about 125 to about 600 nm, about 150 nm to about 500 nm, or about 175 nm to about 400 nm in one embodiment.

[0095] In one embodiment, the RNA nanoparticles described herein exhibit a polydispersity index of less than about 0.5, less than about 0.4, or less than about 0.3. For example, the RNA nanoparticles can exhibit a polydispersity index in the range of about 0.1 to about 0.3.

[0096] In a particularly preferred embodiment of the present invention, the RNA nanoparticle is a lipid nanoparticle, i.e. a particle containing a lipid (particularly a cationic lipid) and RNA. Electrostatic interactions between positively charged liposomes and negatively charged RNA result in the compounding and spontaneous formation of RNA lipid particles. Positively charged liposomes can be synthesized using cationic lipids (e.g., DOTMA) and additional lipids (e.g., DOPE) conventionally. In one embodiment, the RNA lipid particle is a nanoparticle.

[0097] RNA lipid nanoparticles as described herein and compositions comprising RNA lipid nanoparticles can be used to deliver RNA to target tissues after parenteral administration (particularly after intravenous administration). RNA lipid nanoparticles can be prepared using liposomes, which can be obtained by injecting a solution of lipids in ethanol into water or a suitable aqueous phase. In one embodiment, the aqueous phase has an acidic pH. In one embodiment, the aqueous phase comprises acetic acid, for example, in an amount of about 5 mM. In one embodiment, liposomes and RNA lipid nanoparticles comprise at least one cationic lipid and at least one additional lipid. In one embodiment, at least one cationic lipid comprises 1,2-bis-0-octadecene-3-trimethylammonium propane (DOTMA) and / or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP). In one embodiment, at least one additional lipid comprises 1,2-bis-(9Z-octadecene)-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol (Choi) and / or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). In one embodiment, at least one cationic lipid comprises 1,2-di-O-octadecene-3-trimethylammonium propane (DOTMA), and at least one additional lipid comprises 1,2-di-(9Z-octadecene-yl)-sn-glycero-3-phosphoethanolamine (DOPE). In one embodiment, liposomes and RNA lipid nanoparticles comprise 1,2-di-O-octadecene-3-trimethylammonium propane (DOTMA) and 1,2-di-(9Z-octadecene-yl)-sn-glycero-3-phosphoethanolamine (DOPE). Liposomes can be used to prepare RNA lipid nanoparticles by mixing liposomes with RNA.

[0098] RNA lipid nanoparticles targeting the spleen are described in WO 2013 / 143683, which is incorporated herein by reference. It has been found that RNA lipid nanoparticles with a net negative charge can be used to preferentially target spleen tissue or spleen cells, such as antigen presenting cells, particularly dendritic cells. Therefore, after administration of the RNA lipid nanoparticles, RNA accumulation and / or RNA expression occurs in the spleen. Therefore, the RNA lipid nanoparticles of the present disclosure can be used to express RNA in the spleen. In one embodiment, after administration of the RNA lipid nanoparticles, RNA accumulation and / or RNA expression does not occur or does not substantially occur in the lungs and / or liver. In one embodiment, after administration of the RNA lipid nanoparticles, RNA accumulation and / or RNA expression occurs in antigen presenting cells in the spleen, such as professional antigen presenting cells. Therefore, the RNA lipid nanoparticles of the present disclosure can be used to express RNA in such antigen presenting cells. In one embodiment, the antigen presenting cells are dendritic cells and / or macrophages. The diameter of the RNA lipid nanoparticles

[0099] In one embodiment, the lipid solutions, liposomes and RNA lipid nanoparticles described herein include cationic lipids. The term "cationic lipid" as used herein refers to a lipid with a net positive charge. Cationic lipids bind negatively charged RNA to a lipid matrix through electrostatic interactions. Typically, cationic lipids have a lipophilic portion, such as a sterol, an acyl group or a diacyl chain, and the head group of the lipid is typically positively charged. Examples of cationic lipids include, but are not limited to, 1,2-di-0-octadecene-3-trimethylammonium propane (DOTMA), dimethyldioctadecyl ammonium (DDAB); 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium-propane; 1,2-dialkoxy-3-dimethylammonium-propane; dioctadecyl dimethyl ammonium chloride (DODAC), 2,3- Di(tetradecyl)propyl-(2-hydroxyethyl)-dimethylamine (DMRIE), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), 1,2-dioleoyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DORIE) and 2,3-dioleoyloxy-N-[2(sperminecarboxamide)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA). Preferred are DOTMA, DOTAP, DODAC and DOSPA. In a specific embodiment, the cationic lipid is DOTMA and / or DOTAP.

[0100] Additional lipids can be added to adjust the overall positive charge to negative charge ratio and physical stability of RNA lipid nanoparticles. In certain embodiments, the additional lipids are neutral lipids. As used herein, "neutral lipids" refer to lipids with a net charge of zero. Examples of neutral lipids include, but are not limited to, 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramides, sphingomyelin, cephalin, cholesterol, and cerebrosides. In specific embodiments, the additional lipids are DOPE, cholesterol, and / or DOPC.

[0101] In certain embodiments, the RNA lipid nanoparticles include a cationic lipid and an additional lipid. In an exemplary embodiment, the cationic lipid is DOTMA, and the additional lipid is DOPE. Without wishing to be bound by theory, the amount of at least one cationic lipid may affect important RNA lipid nanoparticle properties, such as the charge, particle size, stability, tissue selectivity, and biological activity of the RNA compared to the amount of at least one additional lipid. Therefore, in some embodiments, the molar ratio of at least one cationic lipid to at least one additional lipid is about 10:0 to about 1:9, about 4:1 to about 1:2, or about 3:1 to about 1:1. In a particular embodiment, the molar ratio may be about 3:1, about 2.75:1, about 2.5:1, about 2.25:1, about 2:1, about 1.75:1, about 1.5:1, about 1.25:1, or about 1:1. In an exemplary embodiment, the molar ratio of at least one cationic lipid to at least one additional lipid is about 2:1.

[0102] The charge of the RNA lipid nanoparticles disclosed herein is the sum of the charge present in at least one cationic lipid and the charge present in the RNA. The charge ratio is the ratio of the positive charge present in at least one cationic lipid to the negative charge present in the RNA. The ratio of the positive charge present in at least one cationic lipid to the negative charge present in the RNA is calculated by the following equation: Charge ratio=[(cationic lipid concentration (mol))*(total number of positive charges in cationic lipid)] / [(RNA concentration (mol))*(total number of negative charges in RNA)]. Those skilled in the art can determine the concentration of RNA and the amount of at least one cationic lipid using conventional methods.

[0103] In one embodiment, at physiological pH, the charge ratio of positive charge to negative charge in the RNA lipid nanoparticle is about 1.6: 2 to about 1: 2, or about 1.6: 2 to about 1.1: 2. In a specific embodiment, the charge ratio of positive charge to negative charge in the RNA lipid nanoparticle at physiological pH is about 1.6: 2.0, about 1.5: 2.0, about 1.4: 2.0, about 1.3: 2.0, about 1.2: 2.0, about 1.1: 2.0 or about 1: 2.0.

[0104] It has been found that RNA lipid nanoparticles with this charge ratio can be used for preferentially targeting spleen tissue or spleen cells, such as antigen presenting cells, particularly dendritic cells. Therefore, in one embodiment, after administering the RNA lipid nanoparticles, RNA accumulation and / or RNA expression occur in the spleen. Therefore, RNA lipid nanoparticles of the present disclosure can be used for expressing RNA in the spleen. In one embodiment, after administering the RNA lipid nanoparticles, RNA accumulation and / or RNA expression do not occur or do not occur substantially in the lungs and / or liver. In one embodiment, after administering the RNA lipid nanoparticles, RNA accumulation and / or RNA expression occur in antigen presenting cells in the spleen, such as professional antigen presenting cells. Therefore, RNA lipid nanoparticles of the present disclosure can be used for expressing RNA in such antigen presenting cells. In one embodiment, antigen presenting cells are dendritic cells and / or macrophages.

[0105] According to the present disclosure, the compositions described herein may include salts, such as sodium chloride. Without wishing to be bound by theory, sodium chloride is used as an ion osmotic pressure agent for pre-treating RNA before mixing with at least one cationic lipid. Certain embodiments contemplate alternative organic or inorganic salts of sodium chloride in the present disclosure. Alternative salts include, but are not limited to, potassium chloride, dipotassium phosphate, monopotassium phosphate, potassium acetate, potassium bicarbonate, potassium sulfate, potassium acetate, disodium hydrogen phosphate, monosodium phosphate, sodium acetate, sodium bicarbonate, sodium sulfate, sodium acetate, lithium chloride, magnesium chloride, magnesium phosphate, calcium chloride, and sodium salts of ethylenediaminetetraacetic acid (EDTA).

[0106] Typically, the compositions comprising RNA lipid nanoparticles described herein comprise sodium chloride at a concentration preferably of 0 mM to about 500 mM, about 5 mM to about 400 mM, or about 10 mM to about 300 mM. In one embodiment, the composition comprising RNA lipid nanoparticles contains an ionic strength corresponding to such a sodium chloride concentration.

[0107] The compositions described herein may include stabilizers to avoid substantial loss of product quality, particularly substantial loss of RNA activity during freezing, lyophilization, spray drying, or storage (eg, storage of frozen, lyophilized, or spray dried compositions).

[0108] In one embodiment, the stabilizer is a carbohydrate. As used herein, the term "carbohydrate" refers to and includes monosaccharides, disaccharides, trisaccharides, oligosaccharides, and polysaccharides.

[0109] In an embodiment of the present disclosure, the stabilizer is mannose, glucose, sucrose or trehalose. According to the present disclosure, the RNA lipid nanoparticle composition described herein has a stabilizer concentration suitable for composition stability (particularly suitable for RNA lipid nanoparticle stability and suitable for RNA stability).

[0110] According to the present disclosure, the RNA lipid nanoparticle compositions described herein have a pH value suitable for RNA lipid nanoparticle stability (particularly suitable for RNA stability). In one embodiment, the RNA lipid nanoparticle compositions described herein have a pH value of about 5.5 to about 7.5.

[0111] According to the present disclosure, a composition comprising a buffer is provided. Without wishing to be bound by theory, the use of a buffer maintains the pH value of the composition during manufacture, storage and use of the composition. In certain embodiments of the present disclosure, the buffer can be sodium bicarbonate, monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS), 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine), 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris), N-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine (Tricine), 3-[[1,3-dihydroxy-2- ...

[00136] In some embodiments, the present invention relates to a buffered saline (PBS) buffered saline containing 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid (TAPSO), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES), 1,4-piperazinediethanesulfonic acid (PIPES), dimethylarsonic acid, 2-morpholin-4-ylethanesulfonic acid (MES), 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) or phosphate buffered saline (PBS). Other suitable buffers may be acetic acid in salt form, citric acid in salt form, boric acid in salt form and phosphoric acid in salt form.

[0112] Some embodiments of the present disclosure consider the use of chelating agents. Chelating agents refer to compounds that can form at least two coordinated covalent bonds with metal ions to produce stable water-soluble complexes. Without wishing to be bound by theory, chelating agents reduce the concentration of free divalent ions, otherwise accelerated RNA degradation may be induced in the present disclosure. Examples of suitable chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), salts of EDTA, deferoxamine B, deferoxamine, sodium diethyldithiocarbamate (dithiocarb sodium), penicillamine, calcium pentetate, sodium salt of pentetate, succimer, trientine, nitrilotriacetic acid (nitrilotriacetic acid), trans-diaminocyclohexanetetraacetic acid (DCTA), diethylenetriaminepentaacetic acid (DTPA), bis(aminoethyl)glycol ether-N, N, N', N'-tetraacetic acid, iminodiacetic acid, citric acid, tartaric acid, fumaric acid or its salt. In some embodiments, the chelating agent is EDTA or an EDTA salt. In an exemplary embodiment, the chelating agent is disodium EDTA dihydrate.

[0113] In some embodiments, the concentration of EDTA is about 0.05 mM to about 5 mM,

[0114] In an embodiment, the composition of the present disclosure is a liquid or a solid. Non-limiting examples of solids include frozen forms or lyophilized forms. In a preferred embodiment, the composition is a liquid.

[0115] The RNA described herein, for example formulated into RNA lipid nanoparticles, can be used as or in the preparation of a pharmaceutical composition or medicament for therapeutic or preventive treatment.

[0116] The compositions of the present disclosure can be administered in the form of any suitable pharmaceutical composition. Pharmaceutical compositions are also referred to as pharmaceutical preparations in the art. In the context of the present disclosure, pharmaceutical compositions comprise the RNA described herein, for example formulated into RNA lipid nanoparticles.

[0117] The administration route of nucleic acid vaccine includes, but is not limited to, intramuscular, intranasal, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, intraocular and oral, as well as topical, transdermal, inhalation or suppository or mucosal tissue, such as by lavage of vagina, rectum, urethra, buccal and sublingual tissue. Preferred administration routes include intramuscular injection, intraperitoneal injection, intradermal injection and subcutaneous injection. Genetic constructs can be administered by including, but not limited to, electroporation methods and devices, conventional syringes, needleless injection devices or "microprojectile bombardment gone gun" and other modes.

[0118] The source of immunogenic polypeptides of the present invention may also be living cells that express and / or present immunogenic polypeptides. The cells may be autologous or allogeneic immune cells, such as dendritic cells from the subject to be treated, or the cells may be microbial cells, more preferably bacteria, such as attenuated live Listeria monocytogenes. The expressed immunogenic polypeptide is preferably an immunogenic polypeptide as defined above. The immunogenic polypeptide may be expressed as part of a fusion protein, wherein the immunogenic polypeptide is preferably fused to an endogenous protein of the organism, such as the N-terminal fragment of Listeria monocytogenes LLO or ActA protein. For example, suitable embodiments of Listeria-based vaccines are described in WO2015 / 164121. Bacteria expressing the immunogenic polypeptides of the present invention may be administered orally or parenterally, preferably intravenously.

[0119] In another embodiment of the present invention, the source of the immunogenic polypeptide of the present invention is an autologous or allogeneic dendritic cell (DC) presenting at least one MHC-restricted epitope of the immunogenic polypeptide in the HLA molecule on its surface. For example, such dendritic cells can be prepared in vitro by contacting DC from the patient's blood (e.g., DC isolated from monocytes of the patient / subject) with a composition comprising the immunogenic polypeptide of the present invention and / or loading the composition comprising the immunogenic polypeptide of the present invention. The immunogenic polypeptide contacted with the monocyte or DC is preferably an immunogenic polypeptide as defined above. Drugs that promote DC harvesting, such as Progenipoietin, can be used. TM (Monsanto, St. Louis, MO) or GM-CSF / IL-4. After pulsing the DC with peptide and washing to remove unbound peptide, the DC is reinfused into the patient. In this embodiment, a composition is provided comprising peptide-pulsed DC that presents the pulsed peptide epitopes on HLA molecules on their surface. Alternatively, instead of using autologous cells from the subject, allogeneic DC derived from a precursor human dendritic cell line and designed to deliver antigens may be used, e.g., as described in WO2009 / 019320, WO2014 / 090795, and WO2014 / 006058. Methods of inducing immune responses using ex vivo peptide-pulsed DC are well known to those skilled in the art.

[0120] Another aspect of the present invention relates to a pharmaceutical preparation comprising as an active ingredient a current source of a polypeptide as defined above. More specifically, the pharmaceutical preparation comprises as an active ingredient one or more of the above immunogenic polypeptides selected from the group consisting of ZP protein, homologues thereof and fragments of said ZP protein and homologues thereof, or, alternatively, a gene therapy vector as defined above.

[0121] According to a first embodiment, a pharmaceutical formulation comprising one or more immunogenic polypeptides of the invention is provided. The concentration of the polypeptide in the pharmaceutical composition can vary widely, from less than about 0.1 wt%, usually at least about 1 wt% to up to 20 wt% or more.

[0122] The composition preferably includes at least a pharmaceutically acceptable carrier in addition to the active ingredient. The pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the immunogenic polypeptide or gene therapy vector to the patient. For polypeptides, sterile water, alcohol, fat, wax and inert solids can be used as carriers. Pharmaceutically acceptable adjuvants, buffers, dispersants, etc. can also be included in the pharmaceutical composition.

[0123] According to a particularly preferred embodiment, the pharmaceutical composition comprises an adjuvant, as defined in more detail herein above. The adjuvant incorporated into the composition of the invention is preferably selected from the group of ligands recognized by Toll-like receptors (TLRs) present on antigen presenting cells, including lipopeptides (see, for example, WO04 / 110486), lipopolysaccharides, peptidoglycans, lipoteichoic acid, lipoarabinomannan, lipoproteins (from mycoplasmas or spirochetes), double-stranded RNA (poly I: C), unmethylated DNA, flagellin, CpG-containing DNA, Pam3cysSK4 and imidazoquinoline, as well as chemically modified derivatives of these ligands. The skilled person will be able to determine the exact amount of any of these adjuvants to be incorporated into the pharmaceutical preparation of the invention so that it has sufficient immunogenicity. According to another preferred embodiment, the pharmaceutical preparation of the invention may contain one or more additional components for enhancing CTL immunity, as described above.

[0124] The pharmaceutical preparations of the present invention, such as compositions comprising an immunogenic polypeptide source, their modes of administration and the use of pharmaceutically acceptable excipients are known and customary in the art, such as those described in Remington: The Science and Practice of Pharmacy (Allen, ed., LV 22nd ed., 2012, www.pharmpress.com ).

[0125] Immunogenic polypeptides for use in the present invention, nucleic acids encoding them, or cells expressing them can be prepared using recombinant techniques, such as those described in Ausubel et al. (Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987), and in Sambrook and Russell (2001) Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; both of which are incorporated herein by reference in their entireties. See also Kunkel (1985) Proc. Natl. Acad. Sci. 82:488 (describing site-directed mutagenesis) and Roberts et al. (1987) Nature 328:731-734 or Wells, JA, et al. (1985) Genet. 34:315 (describing cassette mutagenesis). However, more preferably, the immunogenic polypeptides of the invention or nucleic acids encoding them are prepared by chemical synthesis. Chemical synthesis of peptides or nucleic acids is routine practice, and various suitable methods are known to those skilled in the art. Chemical synthesis of peptides or nucleic acids also overcomes the problems associated with recombinant production, which is more difficult to standardize and requires extensive purification and quality control measures.

[0126] In another aspect, the present invention relates to a T cell comprising a T cell receptor that binds to an MHC-peptide complex, wherein the peptide is preferably a peptide comprising or consisting of class I MHC and class II MHC restricted epitopes contained in a natural ZP (preferably hZP3 or hZP3 (23-350)), or a homolog of said one or more polypeptides. For example, such T cells can be obtained by the following method, the method comprising contacting the T cell with an antigen presenting cell expressing a polynucleotide encoding the immunogenic polypeptide of the present invention and / or contacting the T cell with an antigen presenting cell loaded with the immunogenic polypeptide of the present invention; and, optionally, culturing the T cell. The antigen presenting cell (APC) is preferably a dendritic cell (DC). The T cell is preferably a CD8 + Cytotoxic T cells or CD4 +T helper cells. The introduction of a polynucleotide encoding an immunogenic polypeptide into an APC or DC can be performed using any method known to those skilled in the art. Preferably, the polynucleotide according to the present invention is introduced into an APC or DC using transfection. Preferably, the polynucleotide encoding an immunogenic polypeptide has an appropriate control sequence or is contained in an appropriate expression vector. Contacting T cells with the immunogenic polypeptide of the present invention can be performed by any method known to those skilled in the art. Preferably, the immunogenic polypeptide or an epitope contained in the immunogenic polypeptide is presented to CD8 through a class I MHC or class II MHC molecule on the surface of an APC (preferably a DC). + Cytotoxic T cells or CD4 + T helper cells. Those skilled in the art know how to load APCs or DCs with peptides. Any method known to those skilled in the art can be used to culture the T cells. Maintaining T cells under conditions that keep the cells alive should also be interpreted as culturing herein. Preferably, the T cells according to this aspect of the invention are contacted with the immunogenic polypeptide according to the invention as defined in the first aspect of the invention. The in vitro method for obtaining and activating antigen-specific T cells is described in more detail in, for example, WO2017 / 173321. In this regard, the present invention also relates to a composition comprising (activated) T cells according to the invention, and to a method of the invention, comprising administering to a subject a contraceptive effective amount of (activated) T cells described herein or produced by the methods described herein. In an embodiment, administration comprises administering about 10 6 Up to 10 12 About 10 8 Up to 10 11 or about 10 9 Up to 10 10 The (activated) specific T cells. T cells or their compositions are preferably administered intravenously, intraperitoneally, intradermally or subcutaneously. In another embodiment, T cells or their compositions are administered to an anatomical site that drains to a lymph node basin. In another embodiment, administration is into multiple lymph node basins. In a preferred embodiment, the present invention relates to a method for treatment by passive immunization. The method preferably comprises administering an antibody or fragment thereof that specifically binds to an epitope of a human zona pellucida (hZP) protein, preferably an antibody or fragment thereof that specifically binds to an epitope of hZP3 or hZP3 (23-350).

[0127] An antibody that "binds" an antigen of interest is one that binds to the antigen with sufficient affinity so that the antibody can be used as a therapeutic agent targeting cells or tissues expressing the antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the antibody to a "non-target" protein will be less than about 10% of the binding of the antibody to its specific target protein, as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoassay (RIA). With respect to the binding of an antibody to a target molecule, the terms "specific binding", "specific binding to" or "specific for" refer to binding that is detectably different from nonspecific interactions for a specific polypeptide or an epitope on a specific polypeptide target. For example, specific binding can be measured by measuring the binding of a molecule and comparing it to the binding of a control molecule, which is generally a molecule that is structurally similar but has no binding activity. For example, specific binding can be determined by competition with a control molecule similar to the target (e.g., an excess of unlabeled target). In this case, if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target, specific binding is indicated. As used herein, the terms "specifically bind" or "specifically bind to" or "specific for" a particular polypeptide or an epitope on a particular polypeptide target can be represented by, for example, having at least about 10 -4 M, or at least about 10 -5 M, or at least about 10 -6 M, or at least about 10 -7 M, or at least about 10 -8 M, or at least about 10 -9 M, or at least about 10 -10 M, or at least about 10 -11 M, or at least about 10 -12 M or larger K d In one embodiment, the term "specific binding" refers to the binding of a molecule to a specific polypeptide or epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

[0128] The K can be measured at 25 degrees Celsius using a surface plasmon resonance test. d ″ or "K d Value", using BIAcore TM -2000 or BIAcore TM-3000 (BIAcore, Inc., Piscataway, NJ) with antigen CM5 chips immobilized at approximately 10-50 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, Biacore) were activated with N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigens were diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate (pH 4.8) and then injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of coupled protein. After injection of the antigen, 1 M ethanolamine was injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of antibody or Fab (0.78 nM to 500 nM) were injected in PBS containing 0.05% Tween 20 (PBST) at 25°C at a flow rate of approximately 25 μl / min. on ) and dissociation rate (k off ) was calculated by simultaneous fitting of the association and dissociation sensorgrams using a simple one-to-one Langmuir binding model (BIAcore Evaluation Software version 3.2). The equilibrium dissociation constant (K d ) with k off / k on See, for example, Chen, Y., et al., (1999) J. Mol Biol 293:865-881. If the association rate exceeds 10 by the surface plasmon resonance test described above, 6 M -1 S -1 , the association rate can be determined by using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing antigen concentrations at 25°C, as measured in a spectrometer, such as a spectrometer equipped with a stop flow device (Aviv Instruments) or a 8000 series SLM-Aminco spectrometer with a stirred red cuvette (ThermoSpectronic). The "on rate" or "rate of association" or "association rate" or "k" according to the present invention is on "The same surface plasmon resonance technique as described above can also be used, using the BIAcore TM -2000 or BIAcore TM -3000 (BIAcore Inc., Piscataway, NJ) was used to determine.

[0129] The term "antibody" as used herein has a broad meaning and refers to any type of immunoglobulin molecule, including polyclonal antibodies, monoclonal antibodies (including murine, human, human-adapted, humanized and chimeric monoclonal antibodies), antibody fragments, bispecific or multispecific antibodies, dimers, tetramers or multimeric antibodies and single-chain antibodies.

[0130] One embodiment of the present invention relates to a method comprising administering to the subject a composition comprising an anti-ZP antibody (preferably an anti-hZP3 or anti-hZP3 (23-350) antibody), wherein the antibody induces cell killing by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis. As generally understood by those of ordinary skill in the art, these antibody effector functions can be mediated by the Fc portion of the antibody, for example, by binding one or more Fc effector domains to Fc receptors on immune cells with phagocytic or lytic activity or by binding one or more Fc effector domains to components of the complement system. Typically, one or more effects mediated by Fc binding to cells or complement components ultimately result in inhibition and / or depletion of target cells (i.e., cells expressing ZP). Human IgG isotypes IgG1, IgG2, IgG3 and IgG4 exhibit different effector function capabilities. ADCC can be mediated by IgG1 and IgG3, ADCP can be mediated by IgG1, IgG2, IgG3 and IgG4, and CDC can be mediated by IgG1 and IgG3. In the methods described herein, the anti-hZP3 or anti-hZP3(23-350) antibody is preferably an IgG1, IgG2, IgG3 or IgG4 antibody.

[0131] In the methods described herein, anti-hZP3 or anti-hZP3(23-350) antibodies induce in vitro and / or in vivo killing of cells expressing ZP3 protein by antibody-dependent cellular cytotoxicity (ADCC). In the methods described herein, anti-hZP3 or anti-hZP3(23-350) antibodies induce in vitro and / or in vivo killing of cells expressing ZP protein by complement-dependent cytotoxicity (CDC). In the methods described herein, anti-hZP3 or anti-hZP3(23-350) antibodies induce in vitro and / or in vivo killing of cells expressing ZP3 protein by antibody-dependent cellular phagocytosis (ADCP).

[0132] In the methods described herein, anti-hZP3 or anti-hZP3(23-350) antibodies induce in vitro and / or in vivo killing of cells expressing ZP3 protein by apoptosis.

[0133] In the methods described herein, anti-ZP antibodies can be expressed with a range of affinities (K D) binds to human ZP. In one embodiment of the invention, the anti-ZP antibody binds to ZP with high affinity, e.g., K D Equal to or less than about 10 -7 M, for example but not limited to 1-9.9 (or any range or value therein, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9). 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 , 10 -14 , 10 -15 or any range or value therein, as determined by surface plasmon resonance or Kinexa methods practiced by those skilled in the art. An exemplary affinity is equal to or less than 1·10 -8 M. Another exemplary affinity is equal to or less than 1·10 -9 M.

[0134] The antibodies preferably used in the present invention are monoclonal antibodies. Suitable (monoclonal) antibodies can be generated, screened and produced by methods known in the art, such as described in textbooks, such as: Antibodies: A Laboratory Manual, 2nd edition, EA Greenfield, ed., 2014, Cold Spring Harbor Laboratory Press. More specifically, Ranking et al. (1998, Development 125, 2415-2424) described the generation of monoclonal antibody H3.1 against the C-terminal peptide of the hZP3 extracellular domain (comprising amino acids 335-350 of SEQ ID NO: 3). More preferably, the antibodies used in the present invention are humanized, or even more preferably are human monoclonal antibodies, as can be obtained by methods well known in the art, for example, the methods described in Olimpieri et al. (Bioinformatics. 2015; 31(3): 434-435) and Sheehan and Marasco (Microbiol Spectr. 2015; 3(1): AID-0028-2014), respectively, and in the references cited herein.

[0135] Any antibody that binds to the extracellular domain of a ZP protein (e.g., the extracellular domain of hZP3, i.e., hZP3 (23-350), the extracellular protein having the amino acid sequence of SEQ ID NO: 5) can be used in the present invention. Examples of suitable antibodies that can be used in the present invention include, for example, antibodies that are capable of cross-blocking the binding of one or more reference antibodies known to bind to hZP3 (23-350). One such reference antibody known to specifically bind to hZP3 (23-350) is the H3.1 antibody described by Ranking et al. (1998, supra), whose hybridoma is available from ATCC under the accession number: ATCC CRL-2569.

[0136] Therefore, the preferred antibodies used in the present invention are capable of cross-blocking the binding of at least one antibody known to specifically bind to ZP (preferably binding to hZP3, more preferably binding to hZP3 (23-350) or a homologue of said polypeptide). More preferably, the antibody has the ability to cross-block the binding of the H3.1 antibody (Accession No.: ATCC CRL-2569). The ability of an anti-ZP antibody to cross-block the binding of a reference antibody is defined herein as the ability to reduce the binding of a reference antibody to a suitable target molecule comprising the amino acid sequence of ZP, hZP3 or hZP3 (23-350) by at least 10%, 20%, 50%, 75%, 90%, 95%, 99%, 99.9% or 99.99% when the target molecule is first bound by the anti-ZP antibody, or vice versa (i.e., the binding of the anti-ZP antibody is reduced when the target molecule is first bound by the reference antibody). The ability to cross-block can in principle be determined using any type of immunoassay, preferably a competitive immunoassay, including, for example, ELISA, solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli et al., Methods in Enzymology 9: 24-253 (1983) 2); solid phase direct biotin-avidin EIA (see, Kirkland et al. J. Immunol. 137: 3614-3619 (1986)); solid phase direct labeling assay, solid phase direct labeling sandwich assay (see Antibodies: A Laboratory Manual, 2nd ed., 2014; supra); using I 125Labeled solid phase direct label RIA (see, Morel et al., Molec. Immunol. 25(1):7-15 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546-552 (1990)); and directly labeled RIA (Moldenhauer et al. Scand. J. Immunol. 32:77-82 (1990)). Typically, such assays involve the use of a purified target molecule bound to a solid surface, an unlabeled test antibody, and a labeled reference antibody. Competitive inhibition is measured by determining the amount of label bound to the solid surface in the presence of the test antigen binding protein. Typically, the test antibody is present in excess.

[0137] In the methods of the invention described herein, the anti-ZP antibody can be provided as a suitable pharmaceutical composition comprising the anti-ZP antibody and a pharmaceutically acceptable carrier. Suitable carriers and formulations, including other human proteins (e.g., human serum albumin) are described, for example, in Remington: The Science and Practice of Pharmacy, 21st edition, Troy, DB, ed., Lipincott Wlliams and Wilkins, Philadelphia, Pennsylvania, 2006, Part 5, Pharmaceutical Manufacturing, pp. 691-1092, see especially pp. 958-989.

[0138] The anti-ZP antibodies in the methods of the invention described herein can be administered by any suitable route, such as parenteral administration, such as intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, vaginal or rectal) or other routes known to those skilled in the art, as is well known in the art. The anti-ZP antibodies in the methods of the invention described herein can be administered to a patient by any suitable route, such as parenteral administration by intravenous (iv) infusion or bolus injection, intramuscular or subcutaneous or intraperitoneal administration.

[0139] In the methods of the invention, the anti-ZP antibody is administered in a contraceptively effective amount, and can sometimes be from 0.005 mg to about 100 mg / kg, for example, from about 0.05 mg to about 30 mg / kg or from about 5 mg to about 25 mg / kg, or about 4 mg / kg, about 8 mg / kg, about 16 mg / kg or about 24 mg / kg, or for example about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg / kg, but may be even higher, for example about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mg / kg.

[0140] The present invention also relates to a method for contraception in male subjects by targeted therapy, usually by administering a composition comprising an antibody or fragment thereof that can immunospecifically bind to an epitope of human zona pellucida (hZP) protein, preferably an antibody or fragment thereof that can immunospecifically bind to an epitope of human zona pellucida protein 3 (hZP3), wherein the antibody or fragment is part of an immunoconjugate, such as an immunotoxin or an antibody-drug conjugate.

[0141] The term "immunoconjugate" refers to a conjugate in which an antibody or fragment thereof is chemically linked to another molecule. When the molecule linked to the antibody or fragment thereof is a toxin, the immunoconjugate is called an immunotoxin. Immunoconjugates can be used to target the drug moiety to spermatogonia, spermatocytes and / or sperm. Thus, maximum efficacy and minimum systemic exposure are sought. Efforts to design and improve antibody conjugates have focused on the selectivity of monoclonal antibodies (mAbs) and the drug linking and drug release characteristics.

[0142] As will be appreciated by those skilled in the art, the anti-ZP antibody portion may be an anti-ZP antibody having any or all of the features described herein above with respect to the passive immunization embodiment. The immunoconjugate may also comprise an antibody or fragment thereof that is only capable of immunospecifically binding to an epitope of a human zona pellucida (hZP) protein, preferably an antibody or fragment thereof that is capable of immunospecifically binding to an epitope of a human zona pellucida protein 3 (hZP3), without inducing any effector mechanism.

[0143] The immunization method of the present invention may also include administering at least one adjuvant, preferably co-administering at least one adjuvant. The adjuvant may include any adjuvant known in the field of vaccination and may be selected using textbooks such as Current Protocols in Immunology, Wiley-Interscience 2004.

[0144] Adjuvant is intended to include any substance or compound in this article, when it is used in combination with antigen to immunize people or animals, it stimulates the immune system, thereby stimulating, enhancing or promoting the immune response to the antigen, preferably not producing the specific immune response to the adjuvant itself. Compared with the immune response produced for the antigen under the same conditions but in the absence of adjuvant, the preferred adjuvant will enhance the immune response for a given antigen by at least 1.5, 2, 2.5, 5, 10 or 20 times. There is a test in the art for determining the statistical average enhancement of the immune response for a given antigen produced by an adjuvant in an animal or human group relative to a corresponding control group. Adjuvant is preferably capable of enhancing the immune response for at least two different antigens. The adjuvant of the present invention is generally a compound foreign to people, thereby excluding endogenous immunostimulatory compounds of people, such as interleukins, interferons and other hormones.

[0145] A variety of adjuvants are known to those skilled in the art. Suitable adjuvants include, for example, granulocyte-macrophage colony stimulating factor (GM-CSF), incomplete Freund's adjuvant (IFA), Montanide TM ISA-51, Montanide TM ISA 720 (adjuvant produced by Seppic, France), α-galactosylceramide, alum, aluminum phosphate, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (CGP 11637, also known as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamine-L-alanine-2-(1′-2′-di-palmitoyl-sn-glycero-3-hydroxy-phosphoryloxy)-ethylamine (CGP 19835A, also known as MTP-PE), DDA (2-dimethyldioctadecyl ammonium bromide), polyIC, polyA-polyU, RIBI TM , GERBU TM 、Pam3 TM 、Carbopol TM Specol TM 、Titermax TM , tetanus toxoid, diphtheria toxoid, meningococcal outer membrane protein, diphtheria protein CRM 197 Preferred adjuvants include ligands recognized by Toll-like receptors (TLRs) present on antigen presenting cells. Various ligands recognized by TLRs are known in the art, including, for example, lipopeptides (see, for example, WO 04 / 110486), lipopolysaccharides, peptidoglycans, lipoteichoic acid, lipoarabinomannan, lipoproteins (from mycoplasmas or spirochetes), double-stranded RNA (poly I:C), poly ICLC (Hiltonol TM , produced by Oncovir, Inc., USA), unmethylated DNA, flagellin, CpG-containing oligonucleotides, growth factors and cytokines, such as monocytokines, lymphokines, interleukins, chemokines (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, INFa, INF-γ, GM-CSF, LT-a.), Pam3CysSK4 and imidazoquinoline, and derivatives of these ligands with chemical modifications. It is particularly preferred to use poly I: C (poly I: C).

[0146] The method of the present invention can be appropriately combined with immunomodulatory therapy. It is particularly preferred that when the method of the present invention includes administering an immunogenic polypeptide source capable of inducing a cellular or humoral immune response to hZP, the method is combined with immunomodulatory therapy. The immunomodulatory therapy that can be combined with the method of the present invention can be selected from one or more of the following: using checkpoint inhibitors, such as antibodies to PD1, PDL1, CTLA4, TIM-3 and / or LAG-3; using antibodies targeting selected TNF receptor family members, such as antibodies to CD40, 4-1BB, CD137, OX-40 / CD134 and / or CD27; using immunosuppressive cytokines, such as IL-10, TGF-β and / or IL-6; using cytokines, such as IL-7, IL-15 and IL-21 and / or IL-2, because these cytokines have the ability to amplify T cells that experience antigens; using TLR agonists and / or TLR ligands; using agonists of unchanged natural killer T (iNKT) cells, such as synthetic iNKT agonists.

[0147] Another aspect of the present invention relates to a pharmaceutical composition comprising:

[0148] a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP);

[0149] b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or,

[0150] c) an antibody or fragment thereof that specifically binds to hZP;

[0151] As described and defined herein above, wherein preferably, the hZP protein is human zona pellucida protein 3 (hZP3);

[0152] It is usually combined with one or more pharmaceutically acceptable excipients.

[0153] The term "excipient" as used herein refers to a substance that may be present in the pharmaceutical composition of the present disclosure but is not an active ingredient. Examples of excipients include, but are not limited to, carriers, adhesives, diluents, lubricants, thickeners, surfactants, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, or coloring agents. The pharmaceutical composition of the present disclosure may contain salts, buffers, preservatives, and optional other therapeutic agents. In one embodiment, the pharmaceutical composition of the present disclosure comprises one or more pharmaceutically acceptable carriers, diluents, and / or excipients. Preservatives suitable for use in the pharmaceutical composition of the present disclosure include, but are not limited to, benzalkonium chloride, chlorobutanol, parabens, and thimerosal. The term "diluent" refers to a diluting agent and / or a thinning agent. In addition, the term "diluent" includes any one or more of a fluid, a liquid or solid suspension, and / or a mixed medium. Examples of suitable diluents include ethanol, glycerol, and water. The term "carrier" refers to a component, which may be natural, synthetic, organic, inorganic, in which active ingredients are combined to promote, enhance or achieve the administration of the pharmaceutical composition. The carrier used herein may be one or more compatible solid or liquid fillers, diluents or encapsulating materials, which are suitable for administration to a subject. Suitable carriers include, but are not limited to, sterile water, Ringer's solution, lactated Ringer's solution, sterile sodium chloride solution, isotonic saline, polyalkylene glycols, hydrogenated naphthalene, and, in particular, biocompatible lactide polymers, lactide / glycolide copolymers or polyoxyethylene / polyoxypropylene copolymers. In one embodiment, the pharmaceutical composition of the present disclosure includes isotonic saline. Pharmaceutically acceptable carriers, excipients or diluents for therapeutic use are well known in the pharmaceutical field, for example, described in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro, 1985). Pharmaceutical carriers, excipients or diluents may be selected according to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions of the present disclosure preferably comprise one or more adjuvants as defined herein before.

[0154] and kits comprising a package containing one or more such pharmaceutical unit dosage forms and instructions containing printed instructions for administering one or more of said unit dosage forms in / as a contraceptive method in a male subject.

[0155] Another aspect of the invention provides a pharmaceutical kit comprising a package containing a pharmaceutical composition as defined herein and an instruction sheet containing printed instructions for administering the pharmaceutical composition to a male subject for contraception according to the methods disclosed herein.

[0156] According to an embodiment of the present invention, a pharmaceutical kit includes a container, such as a cardboard box, in which a vial containing a composition of the present invention is placed, and an instruction sheet inserted into the container, typically a patient information sheet containing printed information, which may include a description of the form and composition of the pharmaceutical composition contained in the kit, an indication of the intended treatment indication of the product, instructions for use of the product, and information and warnings of adverse reactions and contraindications associated with use. A person of ordinary skill in the art will understand based on the information provided herein that the instructions as part of the kit according to the present invention will typically contain information on treatment indications, uses, treatment regimens, etc. related to the treatment methods of the present invention, as described above.

[0157] Unless otherwise defined, all terms (including technical and scientific terms) used to disclose the present invention have the meaning commonly understood by one of ordinary skill in the art to which the present invention belongs. By way of further guidance, term definitions are included to better understand the teachings of the present invention.

[0158] Unless otherwise clearly stated in the context, "a", "an" and "the" as used herein include both the singular and the plural. For example, "a compartment" means one compartment or more than one compartment.

[0159] As used herein, "about" refers to measurable values ​​(such as parameters, amounts, durations, etc.) and includes variations of + / -10% or less, more preferably + / -5% or less, and even more preferably + / -1% or less from the specific value, as long as these variations are suitable for performing the disclosed invention. However, it should be understood that the value referred to by the modifier "about" is also specifically disclosed.

[0160] As used herein, the terms "comprising", "including", "containing" are synonymous with "including", "comprising", "including", "covering", "covering", and "covering", and they list the existence of the following contents (such as components) and do not exclude or prevent other unmentioned components, features, elements, components, steps known in the art or in the present disclosure.

[0161] Numerical ranges recited as endpoints include all numbers and fractions subsumed within that range, as well as the recited endpoints. The skilled artisan will appreciate that the present invention may include any number of the above-described specific features.

[0162] Example

[0163] Example 1: New expression of zona pellucida protein 3 in normal testis

[0164] The expression of zona pellucida glycoprotein 3 (ZP3) was initially considered to be specific to oocytes and has recently been extended to ovarian, prostate, colorectal, and lung cancers. The successful immunization of transgenic mouse models bearing ZP3-positive ovarian tumors with ZP3 previously highlighted the suitability of ZP3 for cancer immunotherapy. This study was conducted to determine whether any other normal tissues other than the ovary in healthy human and mouse tissues might express ZP3, which is important to rule out off-target effects of ZP3 cancer immunotherapy.

[0165] Materials and methods

[0166] Human tissue samples

[0167] Normal human tissue samples (n=94; subjects aged 30-45 years) were examined from archived paraffin blocks or frozen tissues from the Department of Pathomorphology, Medical University of Bialystok, Poland, and the University Biobank (n=10 / ovary; n=8 / testis; n=7 / myometrial smooth muscle; n=7 / skeletal muscle; n=6 / prostate and epididymis, and n=5 / each tissue type for small intestine, large intestine, liver, pancreas, stomach, lymph nodes, brain, lung, kidney, and breast). Samples were collected during surgery and examined by a pathologist to ensure that they were healthy tissues and did not contain any cancer cells. Human testicular samples (n=6) removed during surgery were from the Biobank, Medical University of Bialystok. None of the male subjects showed infertility or spermatogenic maturation arrest. Testicular architecture and spermatogonia, spermatocytes, and spermatids were identified and differentiated based on the following features: 1) typical size of nuclear structures; 2) location in the epithelium; 3) typical pachytene morphology; and 4) chromatin condensation pattern. Human semen samples (n = 6) were obtained from male patients recruited from the IVF program of the Department of Reproductive and Gynecological Endocrinology of the Medical University of Bialystok, Poland, who were managed for couples with infertility problems (diagnosed as female factors). Semen samples were obtained by masturbation after 3 days of abstinence. After liquefaction at room temperature for 30-60 min, semen parameters were evaluated according to WHO guidelines (WHO 2010), and samples were used for IVF procedures. The remaining samples were used to collect sperm using the swim-up method. Samples with less than 15 × 10 6 The study was approved by the local research ethics committee of the Medical University of Bialystok, Bialystok, Poland.

[0168] Mouse tissue samples

[0169] A total of n=40 fresh or fixed paraffin block tissue samples from normal 3-month-old wild-type C57BL mice were examined (n=10 for ovary, testis, spleen, and skeletal muscle).

[0170] Cell culture

[0171] Murine spermatogenic cells GC-2(spd)ts (CRL-2196; ATCC, Manassas, VA), murine Leydig cell tumor (BLTK-1) (Kananen, Markkula et al. 1996), and mouse Sertoli cell line-1 (MSC-1) (Rebois 1982) cell lines (ATCC) were cultured in DMEM / F12 medium (GIBCO, Paisley, UK) supplemented with 10% (GC-2(spd)ts and BLTK-1) or 5% (MSC-1) fetal bovine serum (FBS; Biochrom, Berlin, Germany), 100 units / mL penicillin, and 100 μg / mL streptomycin (P / S solution; Sigma-Aldrich, St. Louis, MO) at 37°C in a humidified atmosphere with a 5% CO2 content. The primary human Sertoli cell line HSeRC (#4520; ScienCell Research Laboratories, Carlsbad, CA) was cultured in Sertoli cell medium (SerCM, #4521; ScienCell Research Laboratories), and the primary human mesenchymal cell line HLC (#4510; ScienCell Research Laboratories) was cultured in Lesion Cell Medium (LCM; #4511; ScienCell Research Laboratories) at 37°C in a humidified atmosphere with 5% CO2. Three independent cell inoculations were performed for each RNA isolation and immunocytochemistry study, and the experiments were performed in triplicate.

[0172] RNA Isolation

[0173] Total RNA isolation was performed using a TRIzol-based extraction method (Invitrogen, Carlsbad, CA). The quantity and quality of the extracted RNA were determined by absorbance measurement using a NanoDrop (Thermo Fisher Scientific, Waltham, MA). Gel electrophoresis was performed to determine the integrity of the isolated RNA.

[0174] RT-PCR analysis

[0175] Prior to reverse transcription (RT) reaction, 1 μg of total RNA was incubated with deoxyribonuclease (DNase I) (Invitrogen) at room temperature for 30 min and inhibited with 25 mM EDTA solution at 65 °C for 10 min. RT reaction was performed using SensiFAST cDNA synthesis kit (Bioline Reagents Ltd, London, UK) according to the manufacturer's protocol. The first-strand cDNA was used as a PCR template (initial denaturation at 96 °C for 3 min, followed by 35 cycles with cycling conditions of 94 °C for 1 min, 57 °C for 45 s, and 72 °C for 45 s, and finally extension at 72 °C for 5 min). The primer sequences are as follows: mouse Zp3 gene F: GAGCTTTTCGGCATTTCAAG, R: AGCTTATCGGGGATCTGGTT and mouse Ppia gene F: CATCCTAAAGCATACAGGTCCTG, R: TCCATGGCTTCCACAATGTT; human

[0176] ZP3 gene F: ATGCAGGTAACTGACGATGC, R: CCATCAGACGCAGAGAGAAA,

[0177] Human FSHR gene F:TGGGCTCAGGATGTCATCATCGGA,

[0178] R: TGGATGACTCGAAGCTTGGTGAGG, human LHR gene F: CTGAGTGGCTGGGACTATGA, R: CCAAATCAGGACCCTAAGGA; and human PPIA gene F: GCCAAGACTGAGTGGTTGGATG, R: GAGTTGTCCACAGTCAGCAATGG.

[0179] Real-time quantitative PCR (qPCR)

[0180] For real-time qPCR, SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and a Thermocycler 7500 Real-Time PCR System (Applied Biosystems) were used. The reaction conditions were as follows: 2 min at 50°C, 10 min at 95°C, 15 s at 95°C, 1 min at 60°C, and up to 40 amplification cycles. PCR products were analyzed by melting curve analysis and agarose gel electrophoresis to ensure single product amplification. Each reaction product (for RT-PCR and qPCR) was isolated and verified by sequencing analysis. The expression levels of the genes studied were normalized to the housekeeping gene peptidylprolyl isomerase A (PPIA). Primer sequences were as follows: mouse Zp3 F: CCAACGACCAGACTGTGGAA, R: AGGACTATAGCTGCCAGGGT; mouse Ppia F: CATACAGGTCCTGGCATCTTGTC, R: AGACCACATGCTTGCCATCCAG; and human ZP3 F: TGGCAACAGCATGCAGGTA, R: CTGAGTGGCTGGGACTATGA, human FSHRF: GCCAAGAGAGCAAGGTGACA, R: CTCGAAGCTTGGTGAGGACA, human LHR F: CCGGTCTCACTCGACTATCACT, R: AAGCTTGAGATGGGATCACTTTG, and human PPIA F: GTTCTTCGACATTGCCGTCG, R: TGTCTGCAAACAGCTCAAAGG.

[0181] RNAscope in situ hybridization

[0182] Formalin-fixed, paraffin-embedded tissue samples were processed using the RNAscope 2.0HD assay (Catalog No. 310033, Advanced Cell Diagnostics [ACD], Hayward, CA) according to the manufacturer's protocol. Briefly, slides were dewaxed in xylene (2x5 min), 100% EtOH (2x1 min), and air-dried for 5 min at room temperature. Each section was treated with hydrogen peroxide for 10 min at room temperature and then washed twice in distilled water. Slides were boiled in antigen retrieval buffer for 15 min and then immediately immersed in distilled water. Next, slides were washed in 100% EtOH and air-dried. For each section, a barrier was drawn with a hydrophobic pen and incubated in a HybEZ TMProtease was applied in an oven (ACD) for 30 minutes. The slides were washed twice in distilled water. Probes for target transcripts (mouse ZP3: ACD-447551, human ZP3: ACD-442631) and probes for positive (cyclophilin B-PPIB, housekeeping gene, human ACD-313901; mouse ACD-313911) and negative controls (DapB-negative control probe targeting bacterial genes, ACD-310043) were applied. Then, the slides were incubated in an oven at a temperature of 40°C for 2 hours and washed 2x2 minutes in wash buffer. Thereafter, hybridization amplifiers (AMPs) were applied for 30 minutes (AMP1, 3, 5) or 15 minutes (AMP2, 4, 6) at 40°C (AMP 1-4) or room temperature (AMP 5 and 6), with two washes between each step. After the last wash, equal volumes of BROWN-A and BROWN-B reagents were combined and applied to the sections for 10 minutes at room temperature. After washing twice with distilled water, the slides were counterstained in 50% Gill hematoxylin (Vector Laboratories, Burlingame, California, USA) for 2 minutes, then washed in 0.02% ammonia for 10 seconds and twice in distilled water. Dehydrated slides were mounted with Pertex (Histolab Products, Gothenburg, Sweden) (2x2 minutes in 70% EtOH, 2x2 minutes in 100% EtOH, 5 minutes in xylene).

[0183] Immunohistochemical staining

[0184] Monoclonal antibodies against human (isotype IgG1κ) and mouse (isotype IgG2a) ZP3 were generated using hybridoma technology (East, Gulyas et al. 1985, Rankin, Tong et al. 1998). CRL-2462 TM and CRL-2569 TM ) were cultured in DMEM medium containing 4 mM L-glutamine, 1.5 g / L sodium bicarbonate and 4.5 g / L glucose in CELLine bioreactor 1000 mL suspension flasks (Argos Technologies-Cole-Parmer, Vernon Hills, IL), supplemented with 10 mM HEPES, 0.15 mg / ml oxaloacetate, 0.05 mg / ml pyruvate, 0.0082 mg / mL bovine insulin and 0.05 mM 2-mercaptoethanol. 20% FBS was applied to the cell compartment and 1% FBS was applied to the nutrient medium. Depending on the cell growth, the cells were harvested every about 5 days and the harvest was purified.

[0185] Formalin- or Bouin-fixed paraffin-embedded samples were dewaxed and hydrated. Slides were boiled in antigen retrieval buffer (10 mM citrate buffer containing 0.05% Tween20, pH = 6) for 15 minutes. Then, the sections were placed in a humidified chamber and incubated with 3% BSA for 1 hour at room temperature to reduce nonspecific background staining. Next, the slides were placed in a humidified chamber and incubated overnight at 4°C with primary antibodies anti-ZP3 (0.125 μg / mL) or anti-vimentin (ab28028; Abcam, Cambridge, UK; dilution 1:300). The slides were placed in 0.5% H2O2 in PBS and incubated at room temperature for 20 minutes to block endogenous peroxidase activity. DAKO polymer (DAKO EnVision+ System-HRP labeled polymer; Agilent, Santa Clara, CA) was applied to each section and incubated in a humidified chamber for 30 minutes at room temperature. DAB + chromogen (DAKO) was applied for 5 minutes. The slides were washed in dH2O, counterstained in Mayer's hematoxylin (Sigma-Aldrich, St. Louis, MO), dehydrated and mounted with Pertex (Histolab Products). As a control for the antibodies, tissues were incubated with 3% BSA and DAKO polymer to distinguish nonspecific from specific staining.

[0186] Immunocytochemical staining

[0187] GC-2 (spd) ts cells cultured on collagen-coated microscope slide coverslips were washed twice with PBS and fixed in 3.7% paraformaldehyde (PFA) for 20 min. For sperm staining, sperm smears were made and air-dried at room temperature for at least 1 hour. Next, the slides containing sperm were fixed in 4% PFA in PBS for 1 hour. The slides were rinsed in PBS and treated with 0.5% Triton X-100 in PBS for 15 minutes. To block nonspecific binding sites, cells were incubated in blocking solution (2% BSA and 0.05% Tween20 in PBS). Thereafter, cells were incubated with primary mouse monoclonal anti-ZP3 antibody for 1 hour, or double staining with anti-ZP3 antibody diluted in blocking solution and anti-α-tubulin antibody (ab52866, Abcam; dilution 1:300) was performed. After washing, cells were incubated with Alexa Fluor 488 goat anti-mouse IgG (A11029; Thermo Fisher, Waltham, MA; dilution 1:500) or Alexa Fluor 488 goat anti-rabbit IgG (A11034; Thermo Fisher; dilution 1:500) and Alexa Fluor 546 goat anti-mouse IgG (A11030; Thermo Fisher; dilution 1:500) for 45 min. DAPI dye was used as a counterstain to detect cell nuclei. As a control for antibodies, cells were incubated with 2% BSA or Alexa Fluor-488 goat anti-mouse IgG as the primary antibody to distinguish nonspecific staining from specific staining.

[0188] Full field mouse seminiferous tubule staining

[0189] Whole-field mouse seminiferous tubule staining was performed as previously described (Makela, Cisneros-Montalvo et al. 2020). Briefly, three adult WT male mice were sacrificed and seminiferous tubules were fixed with 4% PFA for 2 h at +4°C. After blocking (2% BSA + 10% FBS in 0.3% Triton X-100 in PBS), seminiferous tubules were incubated overnight at +4°C with the following primary antibodies: mouse monoclonal anti-human ZP3 antibody (1 μg / ml), anti-GFRa1 antibody (AF560, R&D Systems, Minneapolis, MN; dilution 1:250), and anti-SALL4 antibody (1:2000, ab29112, Cambridge, UK). After washing, the tubules were incubated with the corresponding secondary antibodies (A11055, A10036, and A31573, Biotech, Carlsbad, CA, USA, all antibodies at a dilution of 1:500) for 1 h at room temperature. Finally, the tubules were arrayed into strips, mounted, and imaged (Zeiss LSM880, Carl Zeiss, Jena, Germany).

[0190] result

[0191] In addition to the ovary, ZP3 is also expressed in spermatogenic cells of normal humans and wild-type (WT) mouse testes

[0192] Quantitative PCR analysis showed that Zp3 was expressed in the ovaries and testes of WT mice ( Figure 1 A-1B, Table 1).

[0193] Table 1. Characterization of ZP3 mRNA levels in different human and mouse tissues / cells.

[0194]

[0195] No Zp3 expression was detected in the spleen and muscle of WT mice used as negative control ( Figure 1 A-1B). Immunohistochemical staining and RNAscope in situ hybridization localized abundant Zp3 protein and mRNA transcripts in oocytes of primary follicles, secondary follicles, and antral follicles of mouse ovaries (respectively). Figure 2 Similarly, abundant Zp3 protein and mRNA were localized in spermatogonia, spermatocytes, round and elongated spermatids in mouse testis (A and 2C, respectively). Figure 2 B and 2D). Mouse primordial follicle oocytes, testicular supporting cells, interstitial cells, and sperm do not express Zp3 ( Figure 2 A-2D). In humans, in oocytes from ovarian follicles (respectively Figure 3 Abundant ZP3 protein and mRNA transcripts were also localized in testicular spermatogonia, spermatocytes, and round and elongated spermatids (A and 3C, respectively). Figure 3 B and 3D). ZP3 expression was not detected in human testicular Sertoli cells and Leydig cells, either at the mRNA level or at the protein level ( Figure 3 B and 3D). Cyclophilin B was used as a positive control and is abundantly expressed in mouse and human ovaries and testes ( Figure 4 , left column). DapB was used as a negative control and was not detected in any gonadal samples ( Figure 4 , right column). Omission of the primary antibody was used as a control for immunohistochemical analysis, and no staining was detected in either mouse or human testis ( Figure 5 AB). To identify Sertoli cells, testicular tissue was immunostained with the Sertoli cell marker vimentin. Positive immunoreactivity for vimentin was observed in the cytoplasm of Sertoli cells, with a thin layer of cytoplasm running through the entire epithelium ( Figure 6 AB). ZP3 mRNA transcripts were not found in human primordial follicle oocytes ( Figure 7A), while in primary ( Figure 7 B) Secondary Figure 7 C) and ventricular ( Figure 7 D) Zp3 expression was localized in ovarian follicles. Zp3 expression was also found in the mouse GC-2spd (ts) immortalized spermatogenic cell line and the ovary of WT mice as a positive control ( Figure 8 A). Zp3 expression was not detected in the mesenchymal tumor cell line BLTK-1 and supporting MSC-1 cells ( Figure 8 A). WT mouse skeletal muscle was used as a negative control for Zp3 ( Figure 8 A). Immunocytochemical studies have revealed that Zp3 is expressed in the cytoplasm of mouse GC-2spd(ts) cells ( Figure 8 B). No staining was detected in control analysis without primary antibody ( Figure 8 B). ZP3 mRNA expression was not detected in human primary supporting cells (HSerC) and stromal cells (HLC) ( Fig. 9 A-9B). As a control, the expression of FSHR and LHR in HSeC and HLC cells was analyzed respectively. HSeC expressed FSHR but not LHR, while HLC expressed LHR but not FSHR ( Fig. 9 A-9B). ZP3, LHR, and FSHR expression were found in human ovaries used as positive controls, but not in human muscle used as negative controls ( Fig. 9 A-9B). GFRa1-positive (GDNF family receptor α-1) spermatogonia are considered to be stem and progenitor cells (SSPCs) of the male germ line (differentiating spermatogonia, cells prior to the A1 spermatogonia that differentiate and commit to sperm development) and are therefore responsible for lifelong sperm production. To examine Zp3 expression in SSPCs, whole-field seminiferous tubule staining was performed on adult mouse testes. No immunoreactivity with mouse monoclonal anti-ZP3 antibody was observed on the basement membrane of the seminiferous epithelium of adult mice, indicating that GFRa1 / SALL4-positive (Spalt-like 4, a pan-spermatogonia marker) SSPCs as well as differentiating progenitor spermatogonia (GFRa1-negative / SALL4-positive) do not express ZP3 ( Fig.10 ZP3 mRNA expression was not detected in human sperm either ( Fig.11 ). ZP3 expression was found in human ovaries used as a positive control, whereas no ZP3 expression was detected in human muscle used as a negative control ( Fig.11 A). No ZP3 staining was detected in human sperm using immunocytochemical analysis ( Fig.11 B).

[0196] Many other normal human and mouse tissues were negative for ZP3

[0197] In other normal human tissues, the expression of ZP3 was not detected by immunohistochemical staining, such as small intestine ( Fig.12 a) Large intestine ( Fig.12 b) Liver Fig.12 c) Pancreas ( Fig.12 d) Stomach Fig.12 e) Lymph nodes ( Fig.12 f) Brain Fig.12 g) Lungs ( Fig.12 h) epididymis ( Fig.12 i) Prostate ( Fig.12 j) Kidneys ( Fig.12 k) Breast ( Fig.12 l), smooth muscle myometrium ( Fig.12 m) and skeletal muscle ( Fig.12 n).

[0198] discuss

[0199] ZP3 has been shown to be expressed in several cancers (ovarian, prostate, colon and lung), which has led to the concept of using it as a target for cancer immunotherapy. Using a transgenic mouse ovarian granulosa cell tumor model, ZP3 immunization has also been shown to be an effective approach for the treatment of ovarian cancer. The employed immunological strategy has the potential to be effective in treating other cancer types that express ZP3. This study aimed to characterize the expression of ZP3 in healthy tissues and the potential for off-target effects in cancer immunity.

[0200] The results of this study show novel expression of ZP3 in spermatogonia, spermatocytes and spermatids of human and mouse testes. However, no expression was found in mature spermatozoa, spermatogonial stem and progenitor cells, and supporting or interstitial cells. In the ovary, ZP3 is required for successful fertilization of the oocyte, but there is no data on the function of ZP3 outside the ovary. Protein ZP3 expression was not found in any other healthy normal tissues except the ovary and testis.

[0201] In the current study, several techniques were used to examine / confirm the expression of ZP3. The localization of ZP3 protein was analyzed using a specific monoclonal antibody, and its presence was confirmed by RNA transcripts in the testis using the sensitive RNAscope in situ hybridization method.

[0202] In female animals, ZP3 immunization induces autoimmune oophoritis and ovarian atrophy (Lou, YH, KKPark, S.Agersborg, P.Alard and KS Tung (2000). "Retargeting T cell-mediated inflammation: a new perspective on autoantibody action." J Immunol 164(10): 5251-5257). When primordial ovarian follicles are selected to grow and become primary follicles, they begin to express ZP antigens in the glycoprotein layer surrounding the oocytes and become susceptible to ZP3-specific antibodies and autoreactive immune cells. It has been confirmed that after antibodies bind to ZP3 proteins in growing or maturing follicles, they induce T cell-mediated inflammation, causing the developing follicles to degenerate. Recently, it has been demonstrated that in actively immunized mice, after careful selection of B cell epitopes, the ZP3 vaccine can induce reversible infertility without adverse effects on the ovaries (Paterson, M., ZA Jennings, MR Wilson and RJ Aiken (2002). "The contraceptive potential of ZP3 and ZP3 peptides in a primate model." J Reprod Immunol 53(1-2):99-107). For the chimeric peptide vaccine, the defined B cell epitope has a key amino acid substitution to prevent cross-reactivity with the native ZP3 T cell epitope, but does not prevent B cell responses to ZP3 (Lou, Y., J. Ang, H. Thai, F. McElveen and KS Tung (1995). "A zona pellucida 3 peptide vaccine induces antibodies and reversible infertility without ovarian pathology." J Immunol 155 (5): 2715-2720). This ZP3 vaccine was able to successfully prevent pregnancy without causing ovarian pathology.

[0203] The expression of the ZP3 antigen in the testis brings the surprising possibility of using ZP3 immunization for male contraception. There is no ZP3 expression in any other normal male tissue as well as in testicular somatic cells, which reduces the risk of concomitant damage to other organs. However, the ZP3 epitope should be carefully selected to avoid damaging testicular tissue and enabling it to cross the blood-testis barrier. Another important feature of this immunization is its reversibility. In addition, since the interstitial cells that synthesize testosterone in the testis do not express ZP3, adverse endocrine side effects may not occur, provided that there is no overall autoimmune response due to adequate selection of epitopes. In addition, since ZP3 expression is not detected in SSPCs and supporting cells, anti-ZP3 male contraceptive treatment is unlikely to destroy spermatogenic stem cells and induce irreversible infertility; therefore, this male contraceptive strategy may be reversible after cessation.

[0204] In summary, we report novel extraovarian ZP3 expression in human and mouse spermatogenic cells and loss of ZP3 expression in a range of normal human and mouse tissues. These findings on loss of ZP3 expression in normal nongonadal tissues provide important context for any ZP3 cancer immunotherapy. Any future clinical trials of ZP3 cancer immunotherapy in males (e.g., prostate, lung, or colorectal cancer) should be approached with caution because of ZP3 expression in the testis. In addition to cancer immunotherapy, the discovery of ZP3 expression in the testis suggests an alternative therapeutic strategy. The exclusive localization of testicular ZP3 expression in spermatogonia, spermatocytes, and spermatids makes ZP3 immunization a promising new target for male immunocontraception. Further studies should also address the functional role of ZP3 in the testis, particularly whether ZP3 immunization has long-term or reversible effects on male fertility. BRIEF DESCRIPTION OF THE DRAWINGS

[0205] Figure 1 : Zp3 expression profile in different wild-type (WT) mouse tissues. qPCR analysis of Zp3 expression in normal mouse testis, ovary, spleen and muscle (A). Zp3 expression was normalized to Ppia expression in the same sample. RT-PCR analysis of housekeeping genes Ppia and Zp3 in normal mouse testis, ovary, spleen and muscle in 2% agarose gel (B). Amplicon sizes are shown on the left.

[0206] M, marker; MU, muscle; OV, ovary; SP, spleen; TE, testis; H2O, nuclease-free water.

[0207] Figure 2: Immunohistochemical localization and RNAscope in situ hybridization of Zp3 in wild-type (WT) mouse ovaries and testes. Localization of Zp3 protein in mouse ovaries (A) and testes (B) and localization of Zp3 mRNA transcripts in mouse ovaries (C) and testes (D). The upper box on the right shows a higher magnification of the lower box, showing ZP3 protein / transcript localization in mouse testes (B, D). In mouse testes, black arrows indicate positive ZP3 protein staining or single transcript localization, white arrows indicate negative supporting cells, and blue arrows indicate negative interstitial cells. Scale bars, 100 μm (A, C) and 50 μm (B, D).

[0208] Figure 3 : Immunohistochemical localization and RNAscope in situ hybridization of ZP3 mRNA transcripts in normal human ovary and testis. Localization of ZP3 protein in human ovary (A) and testis (B) and localization of Zp3 mRNA transcripts in human ovary (C) and testis (D). The upper box on the right shows a higher magnification of the lower box, showing ZP3 protein / transcript localization in human testis (B, D). In human testis, black arrows indicate positive ZP3 protein staining or single transcript localization, white arrows indicate negative supporting cells, and blue arrows indicate negative interstitial cells. Scale bars, 100 μm (A, B) and 50 μm (C, D).

[0209] Figure 4 : Tissue section quality and In situ hybridization specificity analysis. Paraffin sections of wild-type mouse ovaries (AB) and normal human ovaries (CD) and normal mouse testes (EF) and normal human testes (GH) were hybridized with a positive control probe complementary to cyclophilin B (left column) and a negative control probe against the bacterial DapB gene (right column). Sections were counterstained with hematoxylin. Scale bar, 50 μm.

[0210] Figure 5 : Analysis of primary antibody specificity in immunohistochemistry studies. Paraffin sections of wild-type mouse testis (A) and human testis (B) were incubated with 3% BSA and DAKO EnVision+ System-HRP-labeled polymer. Sections were counterstained with hematoxylin. Scale bar, 50 μm.

[0211] Figure 6 : Immunohistochemical localization of vimentin, a supporting cell marker.

[0212] Localization of vimentin in mouse (A) and human (B) testes. Analysis of primary antibody specificity in mouse (C) and human (D) testes. Scale bar, 50 μm.

[0213] Figure 7: RNAscope in situ hybridization of ZP3 mRNA transcripts in normal human ovaries. Localization of ZP3 mRNA transcripts in oocytes of primitive (A), primary (B), secondary (C), and ventricular (D) follicles. The upper right box shows a higher magnification of the lower box, revealing the localization of ZP3 in ventricular follicle oocytes (D). Scale bars, 100 μm (A), 50 μm (B, C), and 200 μm (D). Box magnification, 40x; scale bar, 50 μm.

[0214] Figure 8 : Zp3 expression in the mouse GC-2spd(ts) cell line. 2% agarose gel RT-PCR analysis of housekeeping genes Ppia and Zp3 in GC-2spd(ts) cell line, BLTK-1 cell line, MSC-1 cell line, ovary and muscle (A). Amplicon size is shown on the left. Immunocytochemical localization of Zp3 in the mouse spermatogenic GC-2spd(ts) cell line (B). The lower panel shows the control staining without primary antibody. BLTK-1, mouse Leydig cell tumor; GC-2spd(ts), mouse spermatogenic cell line; M, marker; MSC-1, mouse Sertoli cell line-1; MU, muscle; OV, ovary; H2O, nuclease-free water. Scale bar, 10 μm.

[0215] Fig. 9 : ZP3, FSHR, and LHR expression profiles in human primary Sertoli and Leydig cells. qPCR analysis of ZP3, FSHR, and LHR expression in human primary HSeRC and HLC cells and normal human ovary and muscle (A). Zp3 expression normalized PPIA expression in the same sample. RT-PCR analysis of ZP3, FSHR, LHR, and housekeeping gene PPIA in human primary HSeRC and HLC cells and normal human ovary and muscle in 2% agarose gel (B). HLC, primary human mesenchymal cell line; HSeC, primary human Sertoli cell line; M, marker; MU, muscle; OV, ovary; H2O, nuclease-free water.

[0216] Fig.10 : Immunohistochemical localization of ZP3 in mouse spermatogonial stem and progenitor cells, SSPCs. Confocal microscopy images of whole-field seminiferous tubules of adult mice stained with antibodies against SSPC markers GFRa1 (red), ZP3 (green), and pan-spermatogonial marker SALL4 (blue). White arrows indicate GFRa1 / SALL4-positive SSPCs, and white arrowheads point to GFRa1-negative / SALL4-positive differentiating progenitor spermatogonia. Scale bar 50 μm.

[0217] Fig.11: ZP3 expression in human sperm. RT-PCR analysis of housekeeping genes PPIA and ZP3 in human sperm, ovary and muscle in 2% agarose gel (A). Amplicon sizes are shown on the left. Immunocytochemical localization of ZP3 and α-tubulin in human sperm (B). The lower panel shows control staining without primary antibody. M, marker; MU, muscle; OV, ovary; SP, spleen; H2O, nuclease-free water. Scale bar, 10 μm.

[0218] Fig.12 :Immunohistochemical localization of ZP3 in several normal human tissues. Localization of ZP3 protein in human small intestine (a), large intestine (b), liver (c), pancreas (d), stomach (e), lymph node (f), brain (g), lung (h), epididymis (i), prostate (j), kidney (k), breast (1), smooth muscle myometrium (m), and skeletal muscle (n). Scale bar, 50 μm.

[0219] Fig.13 : Selected hZP3 peptide sequences. Boxes and ovals contain predicted MHC class I and MHC class II binders, respectively, as shown in Tables 2 and 5 and Table 3. Asterisks indicate potential N-linked glycosylation sites, and brackets above the sequence mark regions with O-linked glycan clusters.

[0220] sheet

[0221] Table I : Predicted class I MHC ligands contained in hZP3 protein:

[0222]

[0223]

[0224] Table II: Predicted MHC class II ligands contained in hZP3 protein:

[0225]

[0226]

[0227] Table III: HLA-A2 restricted T cell epitopes of rhZP3 protein:

[0228]

[0229]

[0230] Table IV: Human zona pellucida protein:

[0231]

[0232]

[0233]

Claims

1. A method of treating a male subject by administering to the subject a pharmaceutical composition comprising: a) an immunogenic polypeptide source comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from the amino acid sequence of human zona pellucida protein (hZP); b) a T cell comprising a T cell receptor bound to an MHC-peptide complex, wherein the peptide is a peptide of an amino acid sequence derived from hZP; or, c) an antibody or a fragment thereof that specifically binds to hZP, wherein preferably, the hZP protein is human zona pellucida protein 3 (hZP3); The method is a method for contraception, a method for reducing male fertility, a method for inducing male infertility, a method for inhibiting spermatogenesis, a method for inducing oligospermia, a method for inducing azoospermia, a method for reducing sperm count, a method for inducing a severe oligospermia state, a method for reducing MOT, a method for reducing TMS and / or a method for reducing semen volume.

2. The method of claim 1, wherein the source of the immunogenic polypeptide is a composition comprising: a1) one or more immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO.66-75; and / or, a2) one or more immunogenic peptides comprising or consisting of an amino acid sequence selected from SEQ ID NO.76-85.

3. The method of claim 1, wherein the male subject is a male subject.

4. The method of claim 1, wherein: The immunogenic polypeptide source comprises at least one of the following: a) a proteinaceous composition of matter comprising at least one source of an immunogenic polypeptide comprising at least one of an MHC class I restricted epitope and an MHC class II restricted epitope from an hZP amino acid sequence; b) a nucleic acid molecule encoding the amino acid sequence of the immunogenic polypeptide; c) a cell expressing the immunogenic polypeptide; as well as, d) An antigen presenting cell presenting an MHC-peptide complex, wherein the peptide is a peptide derived from the amino acid sequence of hZP.

5. The method of claim 4, wherein: a) the proteinaceous material composition comprises at least one immunogenic polypeptide comprising a contiguous amino acid sequence of at least 18 amino acids selected from the hZP amino acid sequence, and wherein the contiguous amino acid sequence comprises at least one of a class I MHC restricted T cell epitope and a class II MHC restricted T cell epitope; b) the nucleic acid molecule is: i) a DNA molecule which is an expression construct for expressing the immunogenic polypeptide in human cells; or, ii) an RNA molecule which can be translated into the immunogenic polypeptide in human cells; c) the cell is a microbial cell, preferably a Listeria cell; and, d) the antigen presenting cell is an autologous or allogeneic dendritic cell, which is loaded ex vivo with an immunogenic polypeptide comprising at least one of a class I MHC restricted epitope and a class II MHC restricted epitope of the amino acid sequence of hZP.

6. The method of claim 5, wherein the proteinaceous material composition comprises more than one different immunogenic polypeptide, each immunogenic polypeptide comprising a contiguous amino acid sequence of at least 18 amino acids selected from the amino acid sequence of hZP and having a length in the range of 18-100 amino acids, preferably in the range of 18-60 amino acids in length.

7. The method of claim 1, wherein the hZP is hZP3(23-350).

8. The method of claim 1, wherein the one or more immunogenic peptide sources collectively comprise at least one of: a) at least 50%, 70%, 80%, 90% or 95% of the complete amino acid sequence of hZP3 or hZP3(23-350); and, b) at least 50%, 70%, 80%, 90% or 95% of potential MHC I and / or MHC II epitopes predicted by a computer-based algorithmic bioinformatics tool.

9. The method of claim 16, wherein the method further comprises administering at least one adjuvant, preferably co-administering at least one adjuvant.

10. The method of claim 1, wherein the one or more immunogenic peptide sources are messenger RNAs that are capable of being translated into the immunogenic polypeptides in human cells.

11. The method of claim 11, wherein the one or more immunogenic peptide sources are lipid nanoparticles comprising mRNA and a cationic lipid.

12. The method of claim 1, wherein the antibody or fragment thereof is a humanized or human monoclonal antibody or fragment thereof that specifically binds to hZP3(23-350).